Essential Points {#s1}
================

The timing of puberty has a near-normal distribution in the general population, with the definitions of significantly early or delayed puberty being statistically delineatedPubertal timing is strongly determined by genetics, but it also depends on environmental factors such as body mass, nutrition, psychosocial factors, and, potentially, endocrine-disrupting chemicalsSelf-limited delayed puberty is the commonest cause of delayed puberty in both sexes, but only a small number of genetic causes of self-limited delayed puberty are knownOther genetic causes of delayed puberty include mutations in GnRH deficiency genes and primary hypogonadismGene discovery in delayed puberty is expanding rapidly through both next-generation sequencing and genome-wide association approachesThe importance of the epigenetic control of pubertal timing and how epigenetic mechanisms mediate the influence of environmental factors on the timing of puberty represent a recent and fascinating area of discovery within puberty research

Delayed Puberty: Definition and Morbidity {#s2}
=========================================

Definition {#s3}
----------

In girls the first physical marker for the onset of puberty is most often the transition from Tanner breast stage B1 to B2, which includes early growth of the breast tissue. In boys the respective marker is the change from Tanner genital stage G1 to stage G2, including enlargement of the testes (*i.e.*, achievement of volume \>3 mL or testicular length ≥25 mm) ([@bib1], [@bib2]). Development of pubic hair (pubarche) is usually not regarded as a sign for pubertal onset because pubarche may result from maturation of the adrenal glands (adrenarche), and the appearance of pubic hair can be independent of hypothalamic--pituitary--gonadal (HPG) axis activation.

Adrenarche refers to the maturation of the zona reticularis of the adrenal gland, resulting in increased production of adrenal androgens associated with secondary sexual characteristics such as the development of pubic and axillary hair, body odor, and acne. Adrenarche typically begins at the age of 8 years, but it can occur as early as 6 years. Similar to gonadarche (puberty), the onset of adrenarche appears to be a gradual, progressive maturational process that begins in early childhood and is marked by the further increases of production of adrenal androgens ([@bib3]). Adrenarche may precede true puberty by 1 to 2 years in boys and girls, but the timing of clinical signs can vary. Although adrenarche and puberty often overlap, they are separate processes that are independently regulated ([@bib4], [@bib5]).

Originally, Marshall and Tanner reported the mean (±SD) onset of puberty to be 11.15 (±1.10) years in girls and 11.64 (±1.07) years in boys. These pubertal stages were based on photographic observation of genital development of a longitudinal, but still relatively small, sample of 192 girls and 228 boys living in a children's home. Despite the probably poorly representative nature of this sample, comparable studies in Switzerland ([@bib6], [@bib7]), the United States ([@bib8]), and Denmark ([@bib9]) reported roughly similar mean ages of puberty onset. Although the mean age of onset may be fairly uniform, the onset of puberty takes place across a wide range of ages in normal, healthy adolescents. Several pathological states influence the timing of puberty either directly or indirectly and contribute to this disparity, but the great majority of the variation in pubertal timing cannot be attributed to any clinical disorder. In most populations 95% of girls experience onset of pubertal development between 8.5 and 13 years of age and the same percentage of boys between 9 and 13.5 years of age ([@bib9]). These data have led to the traditional definition of delayed puberty as lack of development of secondary sexual characteristics by the age of 13 years in girls and 14 years in boys. However, these limits do not apply to all ethnic groups.

Because of the downward trend in pubertal timing, further discussed below, in some but not all reports from the United States ([@bib12], [@bib15]) and other countries ([@bib13], [@bib14]), some advocate for younger age cutoffs also for the general population. However, the secular change reported in the general population in the onset of puberty has not been consistently seen in late developing adolescents ([@bib14]) and hence the need to readjust age definitions for delayed puberty in males may not be necessary.

External factors and secular trends in the timing of puberty {#s4}
------------------------------------------------------------

The mean age of menarche in mid-19th century Europe was likely between 17 and 18 years of age ([@bib19]). Starting from the late 19th century to the mid-20th century, a gradual decline in age at puberty has been reported, more convincingly in girls than in boys ([@bib13], [@bib19]), after which this trend may have leveled off. The change in the timing in puberty has likely been the result of better hygiene and nutrition as well as increased stability in socioeconomic conditions.

In recent decades secular changes toward earlier pubertal timing has reemerged, particularly in girls, probably reflecting changes in lifestyle and/or environmental factors, which can either be independent regulators or mediate their effects through genes by environment interactions \[for reviews, see Refs. ([@bib19], [@bib22])\]. Variables such as increased adiposity, insulin resistance, physical inactivity, psychological factors, and changed dietary habits have all been implicated as possible mediators of the observed change in pubertal timing.

The extent to which age at puberty has declined in males during the past few decades is controversial. In the mid-1990s, data from the Third National Health and Nutrition Examination Survey (NHANES III), where genital ratings were performed by visual inspection, reported earlier age at puberty in both boys and girls ([@bib12], [@bib18]) than what previously had been reported from the United States ([@bib26]). However, owing to lack of data on pubertal onset in the previous population-based study (Third National Health Examination Survey) ([@bib10]), some controversy remained as how to interpret the NHANES III findings ([@bib12], [@bib18]). Furthermore, questions have been raised regarding the criteria used for genital staging in NHANES III ([@bib27], [@bib28]). A subsequent secular trend analysis between the Third National Health Examination Survey (which lacked data from the early pubertal stages) and NHANES III did not find clear evidence supporting earlier age at puberty. These data were also reviewed by an expert panel, which concluded that the available data are insufficient in quality and quantity to confirm a recent change in pubertal timing in US boys ([@bib15]). Conversely, at the same time in Europe, in comparison with NHANES III studies, markedly higher ages at pubertal onset in boys have been reported ([@bib6], [@bib7], [@bib14], [@bib29]). Only a few studies contained data to assess secular trend in the timing of puberty in Europe. Of these, earlier studies did not support change in the age at pubertal onset in boys from the mid-1960s to the late 1990s ([@bib9], [@bib29]), whereas more recent studies report some evidence ([@bib14]). The possibility that the increasing rates of obesity contributed to the secular trend toward early puberty onset was originally proposed in the report by Herman-Giddens *et al.* ([@bib16]) in 1997. However, research to date highlights inconsistencies in how obesity has been found to affect pubertal timing, especially in boys, and emphasizes the need for future research in this area.

Associations between delayed puberty and adult health risks {#s5}
-----------------------------------------------------------

Menarche, the onset of first menstruation in girls, represents a distinct event, which is reasonably well recalled into adulthood. Therefore, this marker of puberty timing has often been included in epidemiological studies on the association of puberty timing and adverse health outcomes in the general population ([@bib19]). Such studies report evidence that early age at menarche (AAM) is associated with higher risk of obesity in adulthood ([@bib30]), type 2 diabetes ([@bib30]), and cardiovascular disease ([@bib31]). Other reported associations with early AAM include higher risk for breast cancer ([@bib32]) and all-cause mortality ([@bib33]). Furthermore, inverse genetic correlations are observed with polycystic ovary syndrome, fasting insulin levels, triglyceride levels, and bone mineral density ([@bib34]). In men, owing to the lack of similar, convenient, and frequently recorded markers of puberty timing, reported associations with adverse health outcomes are less well described. Similar to menarche in girls, voice breaking represents a distinct marker of late stage of puberty in boys.

In both women and men, significant genetic correlations are observed between puberty timing and body mass index (BMI) ([@bib35]). This strong interrelationship limits the assessment of their distinct influences on disease risks in traditional observational studies. For instance, large studies using historical growth records (estimating the age at pubertal growth spurt) have identified lower adolescent BMI and earlier puberty timing as predictors of higher breast cancer risk in women ([@bib36]). Conversely, BMI is positively associated with breast cancer risk in postmenopausal women ([@bib37]). Recently, Mendelian randomization analyses including adjustment for genetically predicted BMI have been used to assess the BMI-independent effects of AAM on the risks for various sex steroid--sensitive cancers ([@bib38]). In such BMI-adjusted models, increasing AAM (i.e., later pubertal timing) is associated in particular with lower risk for estrogen receptor--positive breast cancer ([@bib38]). Similarly, later AAM adjusted for genetically predicted BMI is associated with lower risks for endometrial and ovarian cancers. A protective effect of later puberty timing was also reported on risk for prostate cancer in men, independent of BMI ([@bib38]).

In women, but not in men, late pubertal timing has been associated with higher risk for osteoporosis ([@bib39]). The UK Biobank study, comprising ∼500,000 UK individuals, has provided an opportunity to study large-scale disease correlates. A recent study reports 19 adverse health outcomes for late menarche, and following adjustment for potential confounding and mediation by socioeconomic position and adiposity/body composition, six adverse associations remained significant for late menarche ([@bib34]). These included notable novel associations for late menarche with higher risks for early natural menopause, malabsorption/celiac disease, low intelligence, asthma, poor sleep, and poor overall health.

In men older voice breaking was associated with anxiety/panic attacks, asthma, eczema, depression, and poor overall heath ([@bib35]). However, these associations must be approached with some caution because of health selection bias and the possibility of reverse causality. Given that some pathological processes can have their origin long before the diagnosis or presentation of the disease, it remains possible that some factors originating in childhood may have influenced pubertal timing even though the specific condition is not diagnosed until later in life. This may be particularly relevant to the associations between late puberty timing and celiac disease and asthma.

Delayed puberty is often concerning to patients and families. It can affect psychosocial well-being and peer relationships, and these issues are common reasons for initiating sex steroid therapy. However, further studies are still needed to assess fully the psychosocial distress experienced by individuals with delayed puberty, whether this distress has long-term sequelae, and what impact sex steroid supplementation has on these outcomes ([@bib40]). Patients, families, and practitioners are also often worried that delayed puberty may affect adult stature, and many patients present with relative familial short stature along with delayed puberty, which accentuates concerns about adult stature. Adult height can indeed be affected by delayed puberty, but on average it is only slightly below the genetic target ([@bib41]). It remains also unclear whether the reduced adult bone mass and density represent a medical reason to initiate sex steroid therapy for the advancement of puberty ([@bib42]).

Differential Diagnosis of Delayed Puberty {#s6}
=========================================

Common causes of delayed puberty and the prevalence of different etiologies {#s7}
---------------------------------------------------------------------------

The pathogenesis of delayed puberty encompasses several conditions, but it is most commonly due to self-limited delayed puberty (also known as constitutional delay of growth and puberty). There are three main groups of differential diagnoses of self-limited delayed puberty ([Table 1](#tbl1){ref-type="table"}): functional hypogonadism, disorders causing primary hypogonadism, and GnRH deficiency leading to hypogonadotropic hypogonadism (HH), although up to 30 different etiologies underlying delayed puberty have been identified.

###### 

Differential Diagnoses of Self-Limited Delayed Puberty

  Common Causes of:                                                                    
  -------------------------------------------- --------------------------------------- ----------------------------
  Male                                         Isolated HH                             Inflammatory bowel disease
   Klinefelter syndrome                        Klinefelter syndrome                    Celiac disease
   Congenital anorchia/testicular regression   Combined pituitary hormone deficiency   Anorexia nervosa
   Mumps orchitis, coxsackie virus                                                     Hypothyroidism
  Female                                       CNS tumors/infiltrative diseases        Excessive exercise
   Turner syndrome                             Chemotherapy/radiation therapy          
   Premature ovarian insufficiency                                                     
  Both                                                                                 
   Disorders of sexual development                                                     
   Gonadal dysgenesis                                                                  
   Chemotherapy/radiation therapy                                                      
   Galactosemia                                                                        

\[Table modified and reprinted with permission from Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med. 2012;366:443--453.\]

The absence of pathological medical history, signs and symptoms, and a positive family history of pubertal delay in one or both of the parents suggest a diagnosis of self-limited delayed puberty; however, before making the diagnosis, significant pathological conditions must be excluded. These include the aforementioned differential diagnoses of delayed puberty ([Table 1](#tbl1){ref-type="table"}): functional HH, where late pubertal development is due to maturational delay in the HPG axis secondary to chronic disease (found in ∼20% of subjects with delayed puberty), malnourishment, excessive exercise, and psychological or emotional stress; hypergonadotropic hypogonadism, with primary gonadal failure leading to elevated gonadotropin levels due to lack of negative feedback (found in ∼7% of male patients and 26% of female patients with delayed puberty); and permanent HH, characterized by low LH and FSH levels (9% of boys and up to 20% of girls) ([@bib43]).

### Self-limited delayed puberty {#s8}

Self-limited delayed puberty represents the commonest cause of delayed puberty in both sexes. The term "self-limited" has become popular, as in the absence of an identifiable underlying cause pubertal onset usually occurs by the age of 18 years. Moreover, not all patients with such "simple" delayed puberty have constitutional features such as growth delay. Up to 83% of boys and 30% of girls with pubertal delay have self-limited delayed puberty. Individuals with self-limited delayed puberty lie at the extreme end of normal pubertal timing, with the absence of testicular enlargement in boys or breast development in girls at an age that is 2 to 2.5 SD later than the population mean. Additionally, self-limited delayed puberty may also encompass older children with slow pubertal progression, a diagnosis that is aided by the use of puberty normograms ([@bib44]). Self-limited delayed puberty is no longer considered to be a benign developmental variant with no long-term consequences (see above).

Genetic influence on the timing of puberty is of fundamental importance, with epidemiological studies and genetic approaches estimating that 50% to 80% of the variation in pubertal onset is under genetic control ([@bib45]). Although the timing of pubertal onset varies within and between different populations, it is a highly heritable trait, as shown by the high correlation of the timing of sexual maturation within families and in twin studies. Despite this strong heritability, little has been known about the mechanisms that control the timing of pubertal onset or its progression. Attempts to identify key genetic regulators have ranged from genome-wide association studies (GWASs) of AAM examining pubertal timing in healthy women to next-generation sequencing approaches to identify causal mutations in disease cohorts with delayed, absent, or precocious puberty. Although a predominance of males presenting with the condition has been noted, this may be a consequence of referral bias. For the specific genetic causes of self-limited delayed puberty, please see "Single-Gene Disorders Informing the Genetics of Pubertal Timing" below.

### Congenital HH {#s9}

Congenital HH (CHH) is defined by the diagnosis of gonadotropic deficiency during the infant mini-puberty or in adolescence when puberty is absent or arrested ([@bib46]). More rarely, CHH may be suspected in adulthood due to infertility. A picture of "idiopathic" HH with no associated anatomical or functional defect in the HPG axis occurs in 1 to 10 cases per 100,000 births. Kallmann syndrome (KS; HH associated with anosmia) is the most common form of isolated HH ([@bib47]).

The prevalence of CHH is higher in males, estimated at between 1 out of 4000 and 1 out of 10,000 males, and is reported to be twofold to fivefold less frequent in females ([@bib46], [@bib50], [@bib51]). The molecular determinism of this sex difference is not well understood, and it probably reflects the sexual dimorphism of the gonadotropic axis. CHH may be sporadic or familial. CHH was initially considered a monogenic disorder. The understanding of the genetic basis of CHH has greatly advanced during the last 20 years ([Table 2](#tbl2){ref-type="table"}). Several modes of transmission have been described: X-linked recessive transmission, autosomal recessive transmission, autosomal dominant transmission, or transmission linked to an imprinting locus. Because of different causes and incomplete penetrance, there is a wide spectrum of phenotypes, ranging from complete HH, with lack of pubertal development, to partial hypogonadism with an arrest of pubertal development, and even reversible HH in some patients after treatment ([@bib52]). For the various disease mechanisms and specific genetic causes of CHH, please see "CHH" under "Single-Gene Disorders Informing the Genetics of Pubertal Timing" below.

###### 

Genetic Basis of GnRH Deficiency and Associated Features

                                                         OMIM ID                Isolated                                                                                                                                                                                                                       KS   Syndromic                                          Pathogenic Variants   Associated Variants
  ------------------------------------------------------ ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---- -------------------------------------------------- --------------------- ---------------------
  Primary/congenital                                                                                                                                                                                                                                                                                                                                                                         
   *GNRHR/GNRH1*                                         138850/152760          X                                                                                                                                                                                                                                                                                      x                     
   *KISS1R/KISS1*                                        604161/603286          X                                                                                                                                                                                                                                                                                      x                     
   *TACR3/TAC3*                                          162332/162330          X                                                                                                                                                                                                                                                                                      x                     x
   *FGFR1/FGF8*                                          136350/600483          X                                                                                                                                                                                                                              x    Hartsfield                                         x                     x
   *FGF17*                                               603725                 X                                                                                                                                                                                                                              x                                                                             x
   *ANOS1 (KAL1)*                                        300836                                                                                                                                                                                                                                                x                                                       x                     
   *HS6ST1*                                              604846                 X                                                                                                                                                                                                                              x                                                                             x
   *IL17RD*                                              606807                                                                                                                                                                                                                                                x                                                                             x
   *DUSP6*                                               602748                 X                                                                                                                                                                                                                              x                                                                             x
   *SPRY4*                                               607984                 X                                                                                                                                                                                                                              x                                                                             x
   *FLRT3*                                               604808                                                                                                                                                                                                                                                x                                                                             x
   *PROKR2/PROK2*                                        607123/607002                                                                                                                                                                                                                                         x                                                       x                     
   *SEMA3A/SEMA3E/SEMA7A*                                603961/608166/607961                                                                                                                                                                                                                                  x                                                                             x
   *WDR11*                                               606417                 X                                                                                                                                                                                                                              x                                                       x                     
   *CCDC141*                                             616031                 X                                                                                                                                                                                                                              x                                                                             x
   *LEPR/LEP*                                            601007/164160                                                                                                                                                                                                                                              Severe obesity                                     x                     
   *PCSK1*                                               162150                                                                                                                                                                                                                                                     Obesity, ACTH deficiency, diabetes                 x                     
   *DMXL2*                                               616113                                                                                                                                                                                                                                                     Polyendocrinopathy-polyneuropathy syndrome         x                     
   *RNF216/OTUD4*                                        609948/611744                                                                                                                                                                                                                                         x    Gordon Holmes                                      x                     
   *PNPLA6*                                              603197                                                                                                                                                                                                                                                x    Gordon Holmes, Oliver--Mcfarlane, Laurence--Moon   x                     
   *SOX10*                                               602229                                                                                                                                                                                                                                                x    Waardenburg                                        x                     
   *FEZF1*                                               613301                                                                                                                                                                                                                                                x                                                                             x
   *CHD7*                                                608892                 X                                                                                                                                                                                                                              x    CHARGE                                             x                     
   *POLR3A/POLR3B*                                       614258/614366                                                                                                                                                                                                                                              4H                                                 x                     
   *LHB*                                                 152780                 X                                                                                                                                                                                                                                                                                      x                     
   *FSHB*                                                136530                 X                                                                                                                                                                                                                                                                                      x                     
   *NR0B1*                                               300473                                                                                                                                                                                                                                                     Adrenal hypoplasia                                 x                     
  Associated with other pituitary hormone deficiencies                                                                                                                                                                                                                                                                                                                                       
   Congenital                                                                   With or without midline defects; with or without developmental defects                                                                                                                                                                                                                                       
   Secondary                                                                    Tumors: craniopharyngioma, germinoma, astrocytoma, glioma                                                                                                                                                                                                                                                    
                                                                                Rathke pouch cyst                                                                                                                                                                                                                                                                                            
                                                                                Brain (pituitary) irradiation                                                                                                                                                                                                                                                                                
                                                                                Head trauma                                                                                                                                                                                                                                                                                                  
                                                                                Infiltrative diseases: hemochromatosis, histiocytosis, sarcoidosis                                                                                                                                                                                                                                           
   Functional, secondary to                                                     Chronic diseases: gastrointestinal (celiac disease, inflammatory bowel disease) Endocrinopathies: hypothyroidism, hyperprolactinemia, GH deficiency Psychiatric illness: anorexia nervosa Excessive exercise, undernutrition                                                                                 

The clinical presentation of CHH is related to the severity of GnRH deficiency and to associated biological features ([@bib46], [@bib54], [@bib56], [@bib57]). The severity of gonadotropic axis deficiency determines the phenotype at birth but also at adolescence. At least in boys, at birth a suspicion of hypogonadism may be raised by the assessment of genital appearance. In conditions of congenital GnRH deficiency, both fetal and postnatal pituitary gonadotropin secretion is low. Consequently, boys with CHH may have micropenis and cryptorchidism at birth, with prevalence ranging from 7% to 25% ([@bib58]). The incidence of CHH in isolated congenital undescended testes has been reported to be as high as 70% ([@bib46], [@bib59]). Additionally, although puberty is recognized as the maturational process of the reproductive endocrine system that results in achievement of adult body proportion and the capacity to reproduce, mini-puberty has also been increasingly recognized as vital for normal fertility development ([@bib60]). Mini-puberty provides a window of opportunity for evaluation of the functionality of the HPG axis before puberty ([@bib64]).

During childhood, the gonadotropic axis is dormant, and LH is only detectable by ultrasensitive assays, whereas FSH plasma concentrations are variable ([@bib67], [@bib68]). The diagnosis of CHH is difficult to establish during this period ([@bib69]). CHH is frequently diagnosed in adolescence due to a lack of initiation of puberty. The diagnosis of CHH in boys at puberty or in adulthood without clinical signs at birth suggests a partial form of gonadotropic deficiency ([@bib46]). Owing to the absence of a phenotype at birth in females, this correlation is of course not true.

In addition to the endocrine phenotype, CHH may be suspected by the presence of associated clinical features. This association helps to classify CHH into three categories and points toward the underlying pathogenic mechanism ([@bib46]). The first group is composed of isolated CHH. The association of CHH with anosmia defines KS as a second group. Hearing impairment and skeletal abnormalities such as ectrodactyly, synkinesia (upper limb mirror movements), cleft lip/palate, and hypodontia may also be observed in KS. In addition to these relatively common clinical features, CHH may also be a component of a more complex syndrome (syndromic CHH). Obesity, abnormal behavior, ataxia, mental disability, neuropathy, or white matter disorder may be observed in these syndromes. In few cases, CHH may be associated with a neurodegenerative process starting in adolescence ([@bib72]).

Patients with CHARGE syndrome may be associated with central hypogonadism ([@bib73], [@bib74]). CHARGE stands for coloboma, heart malformations, atresia of the choanae, retardation of growth and development, genital anomalies, and ear anomalies (auditory and vestibular) ([@bib75]). Additionally, CHH may be present, and most patients with CHARGE syndrome have olfactory bulb aplasia. CHARGE syndrome has an estimated birth incidence of 1 in 8 out of 500 to 12,000 ([@bib76]). Other infrequently occurring features include characteristic face and hand dysmorphia, hypotonia, arhinencephaly, semicircular canal agenesis or hypoplasia, hearing impairment, urinary tract anomalies, orofacial clefting, dysphagia, and tracheoesophageal anomalies. Multiple sets of diagnostic criteria for CHARGE syndrome have been proposed ([@bib77]). The causative chromodomain helicase DNA binding protein 7 (*CHD7*) gene encodes a chromodomain (chromatin organization modifier domain) helicase DNA--binding protein expressed in the olfactory placode, which gives rise to GnRH neurons, spinal cord, nasopharynx, and eye. This protein may explain some of the organ involvement. Most patients are heterozygous for loss-of-function mutations in *CHD7* ([@bib75]). Loss-of-function mutations in *CHD7* may also be found in patients with CHH without associated syndromic features.

### Central nervous system tumors {#s10}

Tumors of the central nervous system (CNS) causing delayed puberty most commonly interfere with GnRH synthesis or secretion. These include craniopharyngioma ([@bib78], [@bib79]), Langerhans cell histiocytosis ([@bib80], [@bib81]), germinomas, and prolactinomas. Germinomas are the most common extrasellar tumors to cause delayed puberty, although these tumors are a rarity among primary CNS tumors ([@bib82]). Deficiency of other pituitary hormones is commonly associated with these tumors. Associated posterior pituitary hormone deficiencies are often manifested by diabetes insipidus. Treatment of CNS tumors, leukemia, or neoplasms with cranial irradiation may result in gradual development of hypothalamic--pituitary failure ([@bib83]). GH deficiency is the most common component of the radiation-induced hormone disorder, but gonadotropin deficiency also occurs when the radiation dose is high enough. Development of radiation-induced hypothalamic--pituitary failure may take from 1 year to several years to ensue ([@bib84]). The estimated prevalence of gonadotropin deficiency in childhood cancer survivors is 10.8%. The most recent guidelines to be published recommend screening for gonadotropin deficiency in childhood cancer survivors exposed to hypothalamic--pituitary axis radiation at doses ≥30 Gy and in those with a history of tumors or surgery affecting the hypothalamic--pituitary axis region ([@bib85]).

### Developmental defects of the CNS {#s11}

Various malformations affecting the development of the prosencephalon may cause delayed puberty combined with deficiency of any or all other pituitary hormones ([@bib86]). Midline malformations are often associated with optic dysplasia, and an absent septum pellucidum is often found by imaging techniques (septo-optic dysplasia). Other congenital midline defects, which may range from holoprosencephaly to cleft lip and palate, may also be associated with variable hypothalamic--pituitary dysfunction ([@bib86]).

Genetic defects affecting development of the anterior pituitary cause hypopituitarism, including CHH, in some cases. The pituitary transcription factors *HESX1*, *LHX3*, and *SOX2* are vital for early patterning of the forebrain and pituitary, and mutations in these developmental genes result in syndromic hypopituitarism with gonadotropin deficiency in humans. *PROP1* is important for the development of gonadotropin-secreting cells, and autosomal recessive mutations in this gene are the most common cause of combined pituitary hormone deficiency in humans ([@bib87]). *PITX2* is also vital for survival of gonadotrope cell lineage and is required for expression of the gonadotrope-specific transcription factors *GATA2*, *EGR1*, and nuclear receptor subfamily 5 group A member 1 (*NR5A1*).

The nuclear receptor subfamily 0 group B member 1 (*NR0B1*) gene, alternatively known as DAX-1 orphan nuclear receptor (*DAX1*) gene, and *NR5A1*, alternatively known as steroidogenic factor-1 (SF1), are important for the development of the adrenal gland, gonads, ventromedial hypothalamus, and pituitary gonadotrope cells ([@bib88]). Mutations in *NR0B1* cause X-linked adrenal hypoplasia congenita, with associated HH, whereas mutations in *NR5A1* are associated with 46,XY sex reversal or gonadal dysgenesis, and 46,XX is associated with premature ovarian insufficiency ([@bib88]). Leptin and prohormone convertase-1 may also influence GnRH release and processing of the GnRH receptor, with mutations resulting in a phenotype of HH ([@bib89]).

### Functional HH {#s12}

#### Chronic disease. {#s13}

A wide variety of childhood diseases (many with chronic inflammation) such as Crohn disease ([@bib90]), celiac disease ([@bib91]), chronic kidney disease ([@bib92]), cystic fibrosis ([@bib93]), sickle cell disease, and juvenile idiopathic arthritis are associated with an increased likelihood of delayed puberty. This is a result of several factors related to the disease itself, such as malnutrition, hypercortisolemia, and elevated levels of proinflammatory cytokines. In malnutrition and chronic diseases, weight loss below the level of 80% of ideal body weight can cause delayed or arrested pubertal development ([@bib94]). Nutrition plays an important yet uncharacterized role in the control of GnRH secretion. For example, in regional enteritis, gonadotropin secretion remains normal when nutrition is optimally balanced, but a nonoptimal nutritional status will result in a hypogonadotropic state and arrested pubertal maturation ([@bib90]). Poor nutrition also contributes to the decrease in height velocity usually observed in these patients, decreased bone mineral density, and low mood. Chronic renal insufficiency delays pubertal development, but after successful renal transplantation, gonadotropin secretion is usually restored ([@bib95]).

Most endocrinopathies can cause functional HH with delayed puberty, arrested puberty, or functional amenorrhea ([@bib96]). The most common scenario is hypogonadism due to a prolactinoma, and here the pathophysiology is mediated by hyperprolactinemia itself or via interference with the inhibitory effect of dopamine on prolactin secretion, by the suppression of GnRH by excess cortisol, and/or by hyperandrogenemia. Additionally, GH-secreting adenomas, especially macroadenomas, can also compromise the gonadotrophin cells via mass effect, leading to acquired HH in patients with gigantism or acromegaly ([@bib97]). Treating the underlying endocrinopathy usually results in normalization of the HH axis, although this may not recover following treatment of a significant macroadenoma.

#### Anorexia. {#s14}

Anorexia nervosa is usually associated with severe or even fatal weight loss, which is due to distorted body image, obsessive fear of obesity, and avoidance of food. Virtually all patients have primary or secondary amenorrhea ([@bib98]). Functional HH is at least partly due to severe weight loss, but amenorrhea may also precede the onset of weight loss ([@bib99]). The underlying pathophysiology of amenorrhea is due to GnRH deficiency because the LH secretory pattern in pubertal-aged girls with anorexia is similar to that seen in girls during prepuberty: low or absent LH pulses and a blunted LH response to exogenous GnRH ([@bib100]). This may be mediated, at least in part, by leptin, as women with anorexia have also been demonstrated to have lower leptin concentration than do controls ([@bib101], [@bib102]). Long-term pulsatile administration of GnRH has been shown to restore a pubertal pattern of LH secretion, confirming the hypothalamic location of the defect. Administration of leptin can also reverse hypogonadism in women with hypothalamic amenorrhea, suggesting a potential role for leptin in the treatment of anorexia ([@bib102], [@bib103]). Recovery of normal weight will normalize most endocrine and metabolic functions, but amenorrhea may persist for years ([@bib104]).

#### Athletic training. {#s15}

Overly intensive exercise may suppress the HPG axis by inhibiting hypothalamic pulsatile secretion of GnRH, arrest pubertal development, and cause amenorrhea in females ([@bib105]). These disorders often include compulsive endurance training and are common especially among long-distance runners, gymnasts, and ballerinas. HH may develop even when athletes have normal weight but have less fat and more muscle compared with nonathletic individuals. In female athletes with delayed or arrested pubertal development, adrenarche usually takes place at the normal age. The mechanism of delayed puberty is unclear, but interruption of intensive training advances puberty and menarche before any change in body composition or weight, suggesting a direct effect of physical activity on GnRH secretion. However, certain genetic mutations may predispose to the development of all types of functional HH, and there is evidence for overlap between the genetic bases of functional HH and GnRH deficiency ([@bib106]).

### Hypergonadotropic hypogonadism {#s16}

Conditions of primary gonadal failure are listed in [Table 1](#tbl1){ref-type="table"}. Elevated serum gonadotropins occur usually by the time of the physiological age of puberty. During middle childhood, serum gonadotropins may be similar or mildly higher than those from normal controls ([@bib107]). In boys, low serum inhibin B reflects primary germ cell failure.

In gonadal dysgenesis in both males and females, delayed or absent pubertal development may be the presenting complaint, although associated features usually predominate. Turner syndrome is the most common form of hypergonadotropic hypogonadism in females, occurring in 1 in 2000 to 2500 live births ([@bib108]). In Turner syndrome, puberty is usually absent, or otherwise delayed, and is followed by progressive ovarian failure ([@bib109]). Importantly, however, up to 30% of girls will undergo spontaneous pubertal development and 2% to 5% will have spontaneous menses ([@bib110]). About half of girls with Turner syndrome have the 45,X karyotype. Other causes of ovarian dysgenesis include X isochromosome, where abnormal chromosome division results in duplication of identical chromosome arms, most commonly of the long (q) arm. Various deletions and duplications of the short and long arm of the X chromosome are also found in women with primary ovarian insufficiency, with several genes implicated, including fragile X mental retardation 1 (*FMR1*), premature ovarian failure 1B (*POF1B*), diaphanous related formin 2 (*DIAPH2*), forkhead box L2 (*FOXL2*), and bone morphogenetic protein 15 (*BMP15*) ([@bib111]). Point mutations in the extracellular domain of the FSH receptor are mostly restricted to the Finnish population and result in inactivation of the receptor function with primary or secondary amenorrhea ([@bib112]).

In males, testicular abnormalities are characterized by elevated gonadotropin and low inhibin B concentrations, and may present as pubertal delay. The commonest condition underlying hypergonadotropic hypogonadism in males is Klinefelter syndrome (47,XXY), with a prevalence of 1 in 667 live births. Most of those affected will enter puberty spontaneously at a normal age ([@bib113]), but testosterone levels become increasingly deficient by Tanner stages 4 to 5, possibly as a result of secondary regression ([@bib114]). Delayed puberty may be seen in those with a more complex karyotype (48,XXYY, 48,XXXY, 49,XXXXY). Bilateral anorchia may also be due to vanishing testis syndrome.

Many other causes of disorders of sex development are associated with gonadal failure, but discussion of these is beyond the scope of this review ([@bib115]).

Several complex syndromes may have been associated with hypergonadotropic hypogonadism, including Down syndrome, hypogonadism associated with myopathies (myotonic dystrophy and progressive muscular dystrophy), and Prader--Willi ([@bib116]), Werner ([@bib117], [@bib118]), and Alström ([@bib119]) syndromes. In Noonan syndromes and related disorders, testicular abnormalities are less severe ([@bib120]).

#### Gonadotropin receptor mutations. {#s17}

Several homozygous or compound heterozygous loss-of-function mutations in the *LHCGR* gene have been described in males and females ([@bib121]). The presentation in females is usually primary amenorrhea rather than delayed puberty. In XY males, lack of virilization during the fetal development results in a female phenotype with absence of Müllerian structures and absence of Leydig cells in the testis. Serum levels of LH are elevated and FSH levels are normal. Homozygous mutations in the follicle-stimulating hormone receptor (*FSHR*) are extremely rare, affecting mostly females with variable degree of pubertal development and complete ovarian failure. Discovered first in the Finnish population, point mutations in the extracellular domain of the *FSHR* lead to subsequent inactivation of the receptor function, resulting in raised FSH levels ([@bib112]). Whereas up to 40% of Finnish patients with premature ovarian insufficiency have such a mutation, these appear to be rare in other populations. Histological examinations of ovarian biopsies show the presence of follicles in all female patients with FSH receptor defects, whereas only one in four of those with unknown etiology have follicles. Hence, whereas the receptor defect causes a specific arrest in follicular maturation, many patients with hypergonadotropic ovarian failure have true ovarian dysgenesis. The ovarian phenotype in patients with inactivating FSH receptor mutation is informative with regard to the role of FSH in the regulation of follicular development: the early phases of follicular maturation (up to the preantral stage) are independent of FSH, but for the final maturation of the follicle, this gonadotropin is absolutely necessary. Patients with FSH resistance generally have low to normal anti-Müllerian hormone (AMH) values, in contrast to women with primary ovarian insufficiency due to follicular depletion who have very low to undetectable AMH. In patients with FSH receptor mutations, small growing follicles will continue to secrete AMH, depending on the severity of mutation and the resultant stage of follicular arrest ([@bib122], [@bib123]). In males, serum LH and testosterone levels are normal, FSH levels are elevated, and there is variable suppression of spermatogenesis ([@bib124]).

Evaluation of a Patient With Delayed Puberty {#s18}
============================================

Complete clinical evaluation {#s19}
----------------------------

A temporary delay in sexual maturation is not uncommon and may resolve with time, leading to normal development, optimum adult height, and fertility. However, in patients with an underlying organic pathology, early diagnosis and treatment are essential to ensure normal pubertal progress and adequate adult height. A complete personal medical history must be taken in those presenting with delayed puberty, including height and weight charts, nutritional status, medications, history and/or symptoms of chronic disease, and psychosocial functioning ([@bib40], [@bib125]). A thorough history should also note evidence of anorexia and the intensity of athletic training ([Fig. 1](#fig1){ref-type="fig"}). A history of chronic illnesses, such as celiac disease and inflammatory bowel disease, may suggest a temporary or secondary delay of puberty. A complete family history, including childhood growth patterns, age at pubertal onset of both parents and siblings, and any history of infertility, anosmia, and midline abnormalities of parents and siblings, is required, as a positive familial history is common.

> *"There is some evidence that the female HPG axis may be more sensitive than the male HPG axis to environmental factors...."*

![Flowchart for the evaluation of a patient with delayed puberty. CDGP, constitutional delay of growth and puberty; DP, delayed puberty; FT4, free T4; GHD, GH deficiency; PRL, prolactin; TFT, thyroid function test.](er.2018-00248f1){#fig1}

Physical examination must include pubertal stage assessment in both sexes with penile size as well as location, size, and consistency of the testis in boys. Assessment of Tanner stages can help to identify early signs of puberty that have not been previously noticed. Children who have a low weight for height have an increased likelihood of having an underlying condition delaying HPG axis activation. Bilateral cryptorchidism or a small penis at birth and hyposmia or anosmia due to hypoplasia of the olfactory bulbs may suggest CHH. Lack of smell associated with KS can be assessed by means of detailed questioning or objectively by formal olfactory test, such as the Pennsylvania smell test ([@bib126]). Certain other physical signs will increase suspicion of underlying CHH, such as cleft lip or palate, bimanual synkinesia, congenital ptosis and abnormal visual spatial attention, eye movement abnormalities, sensorineural hearing impairment, agenesis of one or several teeth (hypodontia), obesity, and features suggesting the CHARGE syndrome, as well as digital and other skeletal abnormalities ([@bib46]). Delayed cognitive development associated with obesity or dysmorphic features may suggest an underlying genetic syndrome. A history of chemotherapy or radiotherapy may indicate primary gonadal failure or gonadotropin deficiency depending on the specific treatment received.

In CHH the diagnosis is typically made during the second or third decade of life. Common presenting signs are delayed onset of puberty, poorly developed secondary sexual characteristics, eunuchoid body proportions, or infertility ([@bib50]). In some cases, the diagnosis can be suspected before the age of pubertal onset, as discussed above, during the mini-puberty. The presence or absence of "red flag" features remains the strongest discriminator between isolated delayed puberty and HH. The primary red flags are cryptorchidism or micropenis, indicating a lack of prior mini-puberty, but the presence of the other components of KS (*e.g.*, anosmia, cleft lip and palate, unilateral renal agenesis) increases the likelihood of the diagnosis ([@bib46]).

Differential diagnosis between self-limited delayed puberty and CHH in boys who present with delayed puberty is often difficult at the time of referral, as both conditions may present with effectively the same clinical and hormonal features. Only the demonstration of a complete and effective puberty can distinguish isolated delayed puberty and CHH (partial or complete). Analysis of height velocity is very important in the assessment of individuals with delayed puberty ([@bib127]). In most subjects with constitutional delay there is delayed maturation during early childhood, and consequently they may be shorter than their peers. Those delayed puberty subjects who also have poor growth in childhood may not fully exploit their genetic height potential, resulting in an adult height below their midparental target height ([@bib128]), with an average loss of 4.2 cm when untreated ([@bib127]). However, other studies showed only a negligible difference in adult height, even in delayed puberty subjects who have received no intervention ([@bib41], [@bib131]). This may imply a pathophysiological mechanism additional to lack of sex steroids contributing to the growth phenotype in some patients with delayed puberty, but not in others.

In contrast, patients with CHH have steady linear growth during childhood and only become short for their age with absence of the pubertal growth spurt ([@bib138]). However, hypogonadotropic states cannot be ruled out by short stature and slow growth rate. In delayed puberty adrenarche may also occur later than usual, in contrast to the normal age of adrenarche in patients with isolated HH. Bone age in delayed puberty (X-ray film of nondominant hand and wrist with bone age assessed according to defined standards) is usually behind chronological age, but the developmental milestones are achieved at a normal bone age; that is, onset of signs of pubertal development by the bone age of 13 years in girls and 13.5 years in boys. Gonadotropin and testosterone concentrations increase in concert with the development of the bone age. Thus, all stages of pubertal development occur at an age later than usual.

Thus, initial screening in delayed puberty should include bone age, basal LH and FSH (to look for hypergonadotropic hypogonadism), early-morning testosterone ([@bib139]), and biochemical analysis to search for asymptomatic systemic illness \[full blood count, erythrocyte sedimentation rate (or C-reactive protein), renal function, celiac screen, liver function, electrolytes\], and thyroid function test, IGF-I, and prolactin to assess other pituitary hormonal function ([@bib40]). A karyotype is important especially in females with primary hypogonadism. Brain MRI (to examine olfactory bulbs and sulci) is used to exclude olfactory aplasia or hypoplasia or other hypothalamic--pituitary lesions.

Basal gonadotropin levels are often increased in primary hypogonadism due to, for example, Turner or Klinefelter syndrome, but the basal gonadotropin values are not useful in the differential diagnosis of self-limited delay and CHH. Investigation of the differential diagnosis of these latter two conditions may involve a number of physiological and stimulation tests, including assessment of LH pulsatility by frequent sampling, prolactin response to provocation, gonadotropin response to GnRH, testosterone response to hCG, and first morning-voided urine FSH and LH levels ([@bib140], [@bib141]). More recently, a single measurement of inhibin B \<35 pg/mL in prepubertal boys has been shown to discriminate CHH from self-limited delay with high sensitivity ([@bib142]), but the finding has not been replicated in other studies ([@bib143]) and has not been conclusively demonstrated in girls ([@bib144]). Collectively, testicular volume (cutoff of 1.1 mL), GnRH-induced maximal LH (cutoff of 4.3 IU/L), and basal inhibin B level have been proposed as the most effective discriminators of CHH from delayed puberty in adolescent males ([@bib138]). However, follow-up is often warranted before a definitive diagnosis can be made. Other investigations may be required, such as pelvic ultrasound for gonad and uterine assessment and renal ultrasound in X-linked CHH, owing to suspected anosmin 1 (*ANOS1*) mutations that are associated with renal malformation or unilateral agenesis ([@bib46], [@bib53]).

Assessment of the newborn {#s20}
-------------------------

Boys with CHH may present with micropenis and/or cryptorchidism at birth ([@bib65]). Primary hypogonadism may also present at birth with underdeveloped genitalia in male infants when the condition is gonadotropin-dependent, or alternatively as ambiguous or female genitalia when the defect is of early fetal onset resulting in disorders of sex development.

If a suspicion of congenital hypogonadism arises in the first 3 to 6 months of life it can be investigated on the basis of sex steroid and gonadotropin levels without the need for stimulation tests ([@bib65]). Gonadotropin levels in healthy infants start to increase during the first week of life and then decrease toward the age of 6 months, except for FSH levels in girls that remain elevated until 3 to 4 years of age ([@bib60], [@bib66]). Testosterone levels in boys increase in response to LH levels and peak at 1 to 3 months of age, but in girls estradiol levels fluctuate, probably reflecting ovarian follicular growth and atrophy. Estradiol levels in girls decline in the second year of life. Postnatal HPG axis activation during mini-puberty has important roles in both sexes: in males, for penile and testicular growth, and in girls, for maturation of ovarian follicles and an increase in estradiol levels. However, most studies on hormone levels during mini-puberty have had cross-sectional design, and hence the interindividual differences in timing, duration, and magnitude of mini-puberty have remained largely unexplored. Serial blood sampling from healthy infants is problematic because of its invasiveness, and noninvasive urine or salivary sampling is a way around this problem; however, urine and saliva assays are not widely used in clinical routine. Recently, longitudinal data have provided new information about the hormonal patterns, including the timing of the peak hormone levels and the decrease in hormonal activity according to developmental age ([@bib60], [@bib66])

In primary hypogonadism with gonadal dysgenesis, anorchia, or testicular regression, gonadotropin levels in mini-puberty are generally raised, but they may fall to normal levels in later childhood. However, in Turner syndrome, infant girls with the 45,X karyotype have higher FSH levels than do healthy girls, and the levels remain elevated for several years ([@bib107], [@bib145]). In contrast, girls with Turner syndrome with other karyotypes than 45,X often have close to normal FSH levels, suggesting some ovarian feedback effects on pituitary FSH secretion in these patients. Often, infant boys with Klinefelter syndrome (47,XXY karyotype) have normal levels of inhibin B, AMH, and INSL3, suggesting normal Sertoli and Leydig cell function in infancy, although they have elevated LH and FSH levels ([@bib146]).

Newer markers of gonadal function are useful, particularly in males, for diagnosis of hypogonadism, both soon after birth and after mini-puberty is completed ([@bib151]). Inhibin B is a useful marker of Sertoli cell function from the neonatal period into early childhood and can be used to assess male infants with micropenis and/or cryptorchidism, both due to central and primary hypogonadism ([@bib152]). Its use in female infants is less clear ([@bib153]). AMH is strongly expressed by Sertoli cells from the time of testicular differentiation to puberty and at much lower levels in females by the granulosa cells from birth until menopause ([@bib151]). Undetectable AMH and inhibin B are considered diagnostic of anorchia, but low, close to undetectable levels are also seen in severe forms of CHH ([@bib151]). In infant girls, a similar pattern in AMH levels during the first months of life has also been reported, but the levels in girls are significantly lower ([@bib61]). Thus, low sex steroid and gonadotropin levels in an infant \<3 to 6 months of age indicate central hypogonadism with an absence of the normal mini-puberty ([@bib66]). In contrast, high gonadotropins associated with low/undetectable basal testosterone and INSL3 (in boys) are diagnostic of primary hypogonadism ([@bib115]). Outside of the mini-puberty period, useful tests for the investigation of hypogonadism include inhibin B and AMH ([@bib64]).

Genetics of Pubertal Timing in the General Population {#s21}
=====================================================

GWASs in women {#s22}
--------------

The existence of genetic heterogeneity determining the timing of puberty in the general population is supported by several large GWASs. Most of these studies have been based on self-recall of the timing of menarche, and have thus been carried out in women. The first of many loci associated with age of menarche was the gene *LIN28B*, which is a human ortholog of the gene that controls developmental timing in the *Caenorhabditis elegans* through miRNAs. The lin-28 family regulates the biogenesis of let-7 miRNA family members controlling the timing of developmental events and in turn let-7 miRNA controls lin-28 translation. The major allele of the single-nucleotide polymorphism rs314276 (located in intron 2 of *LIN28B*) was associated with earlier AAM and earlier breast development in girls ([@bib154]). However, mutations in *LIN28B* have not yet been identified in human patients with delayed puberty ([@bib155]) or in early puberty ([@bib156]).

In 2010, a large meta-analysis identified 42 (30 new, 2 previously confirmed, and 10 possible) loci for AAM ([@bib157]). In 2014, this was extended to encompass data from genome-wide and custom-genotyping arrays in up to 182,416 women of European descent from 57 studies ([Fig. 2](#fig2){ref-type="fig"}) ([@bib158]). Evidence (*P* \< 5 × 10^−8^) for 123 signals at 106 genomic loci was identified. Many of these loci were associated with Tanner staging in both sexes, suggesting that these data are applicable to both men and women. The largest GWAS to date comprises 1000 Genomes Project--imputed genotype data in up to ∼370,000 women and identifies 389 independent signals (*P* \< 5 × 10^−8^) for AAM. Per-allele effect sizes ranged from 1 week to 5 months. These signals explain ∼7.4% of the population variance in AAM, corresponding to ∼25% of the estimated heritability, suggesting that many of these genetic variants have a low impact in the general population ([@bib38]).

![Possible roles in the HPG axis of several of the implicated genes from GWAS and biological mechanisms for menarche timing \[adapted from Perry *et al.* ([@bib158])\].](er.2018-00248f2){#fig2}

Importantly, genes already identified in rare disorders of puberty were identified from these GWASs. These included the imprinted gene makorin ring finger protein 3 (*MKRN3*), paternally inherited mutations that have been identified as causal in pedigrees of central precocious puberty (CPP), and delta like non-canonical Notch ligand 1 (*DLK1*). *MKRN3* and *DLK1* are to date only the third and fourth genes with mutations identified as causal in pedigrees of CPP, the others being kisspeptin 1 (*KISS1*) and its receptor *KISS1R* (also known as *GPR54*).

Signals in multiple genes already associated with the HPG axis were identified: near the leptin receptor (*LEPR--LEPROT*), which is also immediately upstream of tacykinin receptor 3 (*TACR3*), which encodes the neurokinin B receptor. A further variant ∼10 kb from *GNRH1* approached genome-wide significance. Two signals were found near prohormone convertase 1 and 2 (*PCSK1* and *PCSK2*), indicating a common function of these prohormone convertases in pubertal regulation. Signals in or near several further genes with relevance to pituitary development and function including POU class 1 homeobox 1 (*POU1F1*), teneurin transmembrane protein 2 (*TENM2*), and fibroblast growth factor (FGF) receptor substrate 3 (*FRS3*) and signals representing *cis*-expression quantitative trait loci for leucine-rich repeat--containing G protein--coupled receptor 4 (*LGR4*) and T-box 6 (*TBX6*), which both encode enhancers for the pituitary development factor *SOX2*, were identified.

In addition to leptin signaling, the authors found overlap with several genes implicated in BMI, including fat mass and obesity-associated protein (*FTO*), SEC16 homolog B (*SEC16B*), transmembrane protein 18 (*TMEM18*), and neuronal growth regulator 1 (*NEGR1*). The onset of puberty requires a minimum level of energy availability, whereas increased BMI has been shown to be associated with precocious onset of puberty. However, the molecular mechanisms for this are still unclear. Whether such genes may regulate pubertal timing exclusively via impact on body mass or via other BMI-independent mechanisms is as yet unknown.

Pathway analyses implicated nuclear hormone receptors, particularly those involved in retinoic acid (RA) and *γ*-aminobutyric acid (GABA)--B2 receptor signaling. The active metabolites of vitamin A, all-*trans* RA and 9-*cis* RA, have differential effects on GnRH expression and secretion. Other possible mechanisms linking RA signaling to pubertal timing include inhibition of embryonic GnRH neuron migration and enhancement of steroidogenesis and gonadotropin secretion.

The authors of these GWASs on age of menarche hypothesize that the genetic architecture of the timing of puberty in healthy subjects involves hundreds of common variants. These studies do rely on self-recall of the AAM, which may result in imprecise data.

GWASs in men {#s23}
------------

The major allele of the single-nucleotide polymorphism rs314276 (located in intron 2 of *LIN28B*) was also found to be associated with earlier voice breaking and more advanced pubic hair development in boys and faster tempo of height growth and shorter adult height in both sexes ([@bib154]). More recently, GWASs of pubertal timing have specifically addressed the timing of voice break in males ([@bib38], [@bib154], [@bib157], [@bib158]). Many of these signals have concordant effects on the age at voice breaking, a corresponding milestone in males. However, in women the signals identified had stronger effects on early than on late age of menarche, but in contrast they had larger effect estimates for relatively late than relatively early voice breaking in males ([@bib38]). This would suggest a greater contribution of "normal" genetic variation to early maturation in girls, but to later maturation in boys.

Epigenetic regulation of pubertal timing {#s24}
----------------------------------------

Several different epigenetic mechanisms have been implicated in regulation of the timing of puberty. Experimental data from rats and goats give evidence for changes in histone acetylation and gene methylation leading to altered gene expression during puberty ([@bib159], [@bib160]). Such epigenetic regulators are potential mediators of the effects of the environment on the hypothalamic regulation of puberty. However, the link between environmental factors and epigenetic control of puberty via the hypothalamus has not been fully explained.

Imprinting is a further epigenetic phenomenon implicated in pubertal timing. Imprinted genes influence the timing of human weaning and adrenarche, with paternally-expressed genes promoting delays in childhood maturation and maternally-expressed genes promoting accelerated maturation ([@bib161]). Paternally inherited variants in *MKRN3* and *DLK1* have been found to correlate with AAM in girls and voice breaking in boys from GWASs ([@bib38]), as above. These two imprinted genes have been reported in familial disordered pubertal timing, both of which with paternally inherited mutations identified in pedigrees of CPP ([@bib162], [@bib163]). *MKRN3* is thought to contribute to the puberty "brake" restraining the HPG axis via inhibition of GnRH release. However, neither *MKRN3* nor *DLK1* mutations have been described in the pathogenesis of delayed puberty.

Prader--Willi syndrome (PWS), another syndrome frequently caused by imprinting disorders, is associated with absent or delayed puberty ([@bib164]). Most cases of PWS are caused by deletion of a cluster of imprinted genes (which include *MKRN3*) on the paternally inherited copy of chromosome 15 (paternal deletion) or by inheritance of both copies of this cluster from the mother (maternal uniparental disomy) ([@bib165]). The minority of individuals with PWS undergo precocious puberty ([@bib166]), but most undergo incomplete puberty, expressed as lack of a pubertal growth spurt, HH, cryptorchidism, underdeveloped genitalia, or incomplete menarche ([@bib116]). The rarity of precocious puberty in PWS, despite the absence of expression of *MKRN3*, is probably explained by the effects of other imprinted genes that are inactivated in typical cases of PWS such as MAGE family member L2 (*MAGEL2*) ([@bib167], [@bib168]). This evidence suggests a complex role for imprinted genes in the timing of puberty, and one in which a given gene's activation can be specific both to tissue type and developmental stage ([@bib161], [@bib165]).

Recent evidence highlights the importance in mice of miRNAs (particularly the miR-200/429 family and miR-155) in the epigenetic upregulation of GnRH transcription during the critical period (murine equivalent of mini-puberty) ([@bib169]). Moreover, miR-7a2 has been demonstrated to be essential for normal murine pituitary development and HPG function, with deletion in mice leading to hypogonadotropic infertility ([@bib170]). This is discussed further in "Upstream control of GnRH neuronal function" under "Single-Gene Disorders Informing the Genetics of Pubertal Timing" below.

The effects of environmental changes on the hypothalamic regulation of puberty may be mediated in part via epigenetic mechanisms, and several studies have shown that the pubertal brain epigenome is affected by environmental perturbations ([@bib159]). The effect of possible endocrine-disrupting chemicals (EDCs) on the timing of puberty has been an ongoing concern ([@bib171]). Numerous substances, including polybrominated biphenyls, bisphenol A, atrazine (herbicides), and phthalates, as well as other more common medicines such as paracetamol and betamethasone, have been suggested as possible EDCs responsible for contributing to disruption of pubertal biology. For example, children migrating for international adoption and formerly exposed to the estrogenic insecticide DDT in their country of origin displayed early or precocious pubertal timing.

Whereas the window of opportunity for the effects of EDC exposure was historically considered to be in the late prepubertal period, evidence of fetal and neonatal origin of changes in pubertal timing counters this theory. Prenatal exposure in boys to EDCs such as phthalates is associated with reduced masculinization of genital structures ([@bib172]). Moreover, maternal exposure to EDCs in rodents has been shown to cause epigenetic modifications in testis and other systemic effects, and thus epigenetic changes during fetal life are also a potential mechanism for the hypothalamic effects of EDCs *in utero* ([@bib22]). The effects of EDCs may persist in pregnant rats in not only their unborn fetus but into the next generation as well.

However, a clear mechanism of action for EDCs through the early initiation of the pulsatility of GnRH from the hypothalamus has not been conclusively demonstrated. Studies are complicated by the likely differing, and possibly divergent, influence of different doses and combination of EDCs and differing effects depending on age and length of exposure ([@bib173]). One recent study has demonstrated alteration in the hypothalamic expression of GnRH, LH, and upstream transcriptional regulators of GnRH including organic cation transporter 2 (Oct-2) and thyroid transcription factor-1 (Ttf-1) in female mice where their mothers were exposed to arsenic during pregnancy ([@bib174]). These changes were associated with earlier vaginal opening, a marker of puberty onset in rodents.

Sexual dimorphism in pubertal timing {#s25}
------------------------------------

There are fundamental differences between males and females in the dynamics of the reactivation of the gonadotropic axis at puberty onset. This biological reactivation of the HPG axis occurs earlier in girls than in boys. In females, estradiol increases together with increasing LH and FSH. In males, the secretion of testosterone increases shortly after the increase in the plasma concentration of LH and FSH.

In boys during puberty, plasma testosterone concentrations increase dramatically ([@bib175]). The pubertal increase in testicular size results primarily from more proliferating and differentiating germ cells and, to a lesser extent, an increase in Sertoli cells. In early and mid-puberty there is a pronounced diurnal rhythm with a morning peak in measurable testosterone, but this is less pronounced in later puberty and declines gradually with age, probably due to decreased day/night ratios of gonadotropins ([@bib68], [@bib176]). In girls, a hormonal dialogue between gonads, hypothalamus, and pituitary contributes to the progressive activation of the gonadotropic axis until the end of puberty, with a gradual increase in GnRH stimulation resulting first in nocturnal LH secretion, with a cyclical pulsatile LH pattern including an LH surge establishing even before menarche ([@bib177]).

These sex differences may be related to differing hormonal status, but they could also be a feature of the sexual dimorphism of the brain. In mice the expression of Kiss1 in the anteroventral periventricular nucleus is much more pronounced in females, whereas its promoter methylation levels are significantly higher ([@bib178]). However, the latter may act as a block to repressive transcription factors, thus accounting for the increase in kisspeptin expression. Many genetic variants associated with AAM are also associated with age at voice breaking in males with the same direction of effects, as discussed above ([@bib38]). As a consequence, early-maturing girls tend to have early-maturing brothers, and late‐maturing boys tend to have late‐maturing sisters, but the extent to which these variants have an effect may differ between the sexes.

There is some evidence that the female HPG axis may be more sensitive than the male HPG axis to environmental factors such as changes in fat mass, such as in conditions of functional hypogonadism due to weight loss or excessive exercise, and in central precious puberty due to increased BMI, where women tend to be affected more than men ([@bib179]). Sex-specific differences have also been identified in a rodent model of the first gene identified by GWASs of pubertal timing, *Lin28*. Male *Lin28b* loss-of-function and male *let-7* gain-of-function, but not female, mice displayed alteration of pubertal timing, with later preputial separation (a marker of pubertal onset in male rodents) than in controls. In contrast, both male and female *Lin28a* gain-of-function mice displayed late onset of puberty. Taken together, these data point toward a complex system of regulation by *Lin28a*, *Lin28b*, and *let-7* in mice, in which *Lin28b* and *let-7* can impact both puberty and growth in a sex-specific manner, raising the possibility that this pathway may contribute to differential regulation of male and female growth and puberty in humans ([@bib180]).

Role of body mass {#s26}
-----------------

There has been a large body of research into the observed secular trend toward an earlier age of pubertal onset in the developed world. It is clear that nutrition plays an important role, with a positive correlation repeatedly demonstrated between age at puberty onset and childhood body size, particularly in girls. Lower age of both B2 development and menarche has been consistently associated with increased body mass. Higher BMI values were seen in early maturers and lower average BMI in late maturers in both white and Afro-Caribbean girls. This was quantified in a large cohort of children (n = 3650), with 1 BMI unit increase between the ages of 2 and 8 years being associated with a 0.11 year advancement in the timing of puberty in both sexes, as measured by peak height velocity ([@bib181]). In contrast, undernutrition in females, for example in chronic disease or anorexia nervosa, can result in a delay in both the onset and tempo of puberty.

In boys the data are less consistent, with some studies having noted an earlier onset of puberty with greater adiposity and some with a later onset. In particular, more European studies have noted the former trend, whereas North American studies have more often shown the latter ([@bib14]). More recent data from the United States have shown a far more complex relationship between fat mass and pubertal timing, with overweight status being associated with earlier pubertal onset but obesity being associated with later onset ([@bib182]). These effects also varied between ethnic groups. It is hypothesized that greater BMI in boys leads to earlier pubertal timing up to the threshold at which obesity occurs. Obesity may lead to later pubertal timing due to suppression of the HPG axis or via adiposity leading to excess aromatase activity and increased conversion of testosterone to estrogen in boys.

The relationship between fat mass and pubertal timing is mediated, at least in part, through the permissive actions of the metabolic hormone leptin, a key regulator of body mass, produced from white adipose tissue. Serum leptin concentrations rise in early female puberty and are required for normal reproduction ([@bib183]). Humans and mice lacking leptin (*Lep*^*ob/ob*^) or the leptin receptor (*LepR*^*db/db*^) fail to complete puberty and are infertile ([@bib184]). The action of leptin in influencing GnRH secretion is not clear-cut. In males, leptin concentrations decrease during puberty. However, leptin does not act directly on GnRH neurons, as they do not express the LepR, but it appears to regulate GnRH neurons indirectly by its action on the hypothalamus via cells that are afferent to GnRH neurons ([@bib185]). Such cells may include LEPR-expressing GABA neurons from the arcuate nucleus (ARC), or via cells that interact morphologically with them, at least in part via the action of nitric oxide (which is required for its action) and via kisspeptin/neuropeptide Y (NPY) neurons ([@bib186]). Leptin administration has also been shown to increase mean LH levels and LH pulse frequency, as well as ameliorate the phenotypic features, in women with hypothalamic amenorrhea ([@bib103]).

Additionally, NPY is involved in many CNS functions, including appetite control and reproduction. NPY modulates GnRH binding to anterior pituitary GnRH receptors and acts at the level of the median eminence to stimulate GnRH secretion from GnRH axon terminals, thus potentiating LH secretion in response to GnRH. NPY plays an important role in the metabolic control of fertility. A chronic increase in NPY tone inhibits LH and FSH, delays sexual maturation, and suppresses estrous cyclicity in rodents, but acute changes in NPY may have variable effects depending on the levels of sex steroid production. Evidence from primate studies suggests that NPY may have a contributory role in the break restraining the onset of puberty in primates ([@bib187]).

> *"Genetic mutations in \>30 separate genes resulting in severely delayed or absent puberty have now been described...."*

Ghrelin and other gut-derived peptides may also form part of the mechanism by which energy homeostasis regulates reproductive development. Ghrelin is the endogenous ligand for the GH secretagogue receptor and is produced primarily by gastric mucosa. Ghrelin circulates in the blood and stimulates the secretion of GH, prolactin, and adrenocorticotropic hormone from the pituitary as well as hypothalamic control of food intake ([@bib188]). Animal studies demonstrate that centrally or peripherally administered ghrelin reduces LH pulse frequency in ovariectomized rats and rhesus monkeys and decreases basal LH concentrations in intact rats and sheep ([@bib191]). Both low birth weight and prematurity are associated with earlier onset of puberty, particularly in those children with a rapid increase in length or weight in the first 2 years of life. It remains unclear, however, whether childhood obesity, insulin resistance, excess androgens, or other factors may explain this association.

Despite this evidence, additional data point to a downward trend in the age of puberty onset that is independent of BMI ([@bib192]). Moreover, although an ongoing strong secular trend toward earlier attainment of B2 has been recognized, the age of menarche in recent years, at least in Northern European studies, has not declined to the same extent. Indeed, as detailed above, some studies suggest that during the last decade the age of menarche and of completion of puberty in males in some populations has become skewed toward later ages. These data may imply that the increase in fat mass alone cannot explain this secular trend and suggest a role for factors that have an estrogen-like effect, without central activation of the HPG axis.

Single-Gene Disorders Informing the Genetics of Pubertal Timing {#s27}
===============================================================

Deletion mapping, homozygosity mapping in consanguineous kindreds with multiple affected members, targeted sequencing projects, and, more recently, next-generation sequencing approaches in patients with CHH and familial precocious puberty have led to the identification of some of the key regulators of the HPG axis. Genetic mutations in \>30 separate genes resulting in severely delayed or absent puberty have now been described, and several important gene discoveries have been made recently in patients with CPP. These genes include *ANOS1* (OMIM 300836), FGF receptor 1 (*FGFR1*, OMIM 136350), *FGF8* (OMIM 600483), prokineticin 2 (*PROK2*, OMIM 607002), prokineticin 2 receptor (*PROK2R*, OMIM 607123), *CHD7* (OMIM 608892), NMDA receptor synaptonuclear signaling and neuronal migration factor (*NSMF*, OMIM 608137), *GNRH1* (OMIM 152760), GnRH receptor (GNRHR, OMIM 138850), *KISS1* (OMIM 603286), *KISS1R* (OMIM 604161), tacykinin 3 (*TAC3*, OMIM 162330), *TACR3* (OMIM 162332), semaphorin 3A (*SEMA3A*, OMIM 603961), SRY-box 10 (*SOX10*, OMIM 602229), IL-17 receptor D (*IL17RD*, OMIM 606807), FEZ family zinc finger 1 (*FEZF1*, OMIM 613301), WD repeat domain 11 (*WDR11*, OMIM 606417), AXL receptor tyrosine kinase (*AXL*, OMIM 109135), heparin sulfate 6-*O*-sulfotransferase 1 (*HS6ST1*, OMIM 604846), and *FGF17* (OMIM 603725) in HH ([@bib49], [@bib51], [@bib57], [@bib193]), and *MKRN3* (OMIM 603856), *KISS1R* (OMIM 604161), and *DLK1* (OMIM 176290) in CPP ([@bib162], [@bib163], [@bib206]). These genes are involved in the control of GnRH neuronal migration and differentiation, GnRH secretion, or its upstream or downstream pathways.

CHH {#s28}
---

As described above in "Congenital HH" under "Differential Diagnosis of Delayed Puberty," CHH may be sporadic or familial, although sporadic forms are found far more commonly. Familial CHH was initially considered a monogenic disorder with several modes of transmission described: X-linked recessive transmission, autosomal recessive transmission, autosomal dominant transmission, or transmission linked to an imprinting locus ([Table 2](#tbl2){ref-type="table"}). Although CHH cases are mainly sporadic, a detailed analysis of the pedigree may be informative when making the diagnosis.

### Recessive transmission {#s29}

Isolated CHH is transmitted as a recessive autosomal trait due to mutations in three pairs of neuropeptides/receptors. Loss-of-function mutations in *KISS1* (OMIM 603286) and its receptor *KISS1R* (OMIM 604161), as well as neurokinin B encoded by *TAC3* (OMIM 162330) and *TACR3* (OMIM 162332) have been described in informative families by linkage analysis. Mutations in *GNRH1* (OMIM 152760) and *GNRHR* (OMIM 138850) have been characterized by a candidate gene approach. An identical variant in both alleles suggests that parents are consanguineous but heterozygote composite variants are more frequent than homozygous variants in isolated CHH. The most frequent pathogenic variant in *GNRHR* (p.Gln106Arg) causes only a partial inactivation of the receptor activity that explains the relatively high frequency of this variant in the general population, with a minor allele frequency of 0.3%.

### X-linked transmission {#s30}

This mode of transmission has been observed only in KS (CHH with anosmia). *ANOS1* (OMIM 300836) is the only KS gene located on the X-chromosome reported to date. Boys with the *ANOS1* mutation are affected whereas females are unaffected but carriers.

### Autosomal dominant transmission {#s31}

Very rare variants in several autosomal genes have been reported in the dominant form of KS. For some of these genes, the transmission is caused by a monoallelic pathogenic mutation, whereas in others an additional genetic event is awaited to fully explain the phenotype. Dominant transmission of CHH is more frequent in KS than in isolated CHH. This mode of transmission is relatively surprising for a reproductive disorder causing infertility in adulthood. Such mutations may give rise to a partial phenotype or one with variable severity of gonadotropin deficiency. In the same family, isolated gonadotropic deficiency, KS, or isolated anosmia may be observed.

The molecular genetic understanding of CHH/KS has advanced tremendously in the past 20 years since the first KS gene, *ANOS1* (formerly *KAL1*), was identified by a positional cloning strategy in 1991. Most recent advances have stemmed from the screening of large cohorts of patients using next-generation sequencing techniques. These studies have led to the definition of two groups of genes with monoallelic variants: the first consists of genes in which rare monoallelic pathogenic variants have been confirmed by several independent studies; the second comprises genes in which monoallelic variants of unknown significance are more frequent in the patient group as compared with the control population ([@bib75]). Associated clinical features such an ectrodactyly may be highly predictive of a pathogenic variant ([@bib209]) \[[Table 3](#tbl3){ref-type="table"} ([@bib209])\].

###### 

Syndromes Associated With Pubertal Delay

                                                           Phenotype                                                                                                                                                                     Genetic Defect
  -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  Prader--Willi syndrome ([@bib210])                       Mental retardation, morbid obesity, hypotonia                                                                                                                                 Deletions within paternally imprinted 15q 11.2--12 region
  Bardet--Biedl syndrome ([@bib211])                       Mental retardation, obesity, retinitis pigmentosa, postaxial polydactyly                                                                                                      *BBS 1-11* (multiple loci) 20p12, 16q21, 15q22.3--23, 14q32.1
  Biemond syndrome ([@bib212])                             Iris coloboma, polydactyly, short stature                                                                                                                                     
  CHARGE anomaly ([@bib213])                               Coloboma, heart malformations, choanal atresia, growth retardation, genital anomalies and ear anomalies, HH, olfactory bulb aplasia, hypoplasia                               *CHD7*
  Adrenohypoplasia congenita ([@bib214])                   Primary adrenal deficiency                                                                                                                                                    *NR0B1*
  Septo-optic dysplasia ([@bib215])                        Small, dysplastic pale optic discs, pendular nystagmus, midline hypothalamic defect with diabetes insipidus, GH, ACTH, TSH, and LH/FSH deficiency, absent septum pellucidum   *HESX1*
  Solitary median maxillary incisor syndrome ([@bib216])   Prominent midpalatal ridge                                                                                                                                                    *SHH 7q3*
  Börjeson--Forssman--Lehmann syndrome ([@bib217])         Mental retardation, gynecomastia, moderate short stature, truncal obesity                                                                                                     *PHF6*
  Gordon Holmes syndrome ([@bib218])                       Cerebellar ataxia, dementia, chorioretinopathy, anterior hypopituitarism                                                                                                      *RNF216/OTUD4*
  *PNPLA6*                                                                                                                                                                                                                               

For another group of patients, it is not possible to affirm the link between genotype and phenotype. The incomplete penetrance observed for these variants of unknown significance has led investigators to propose an oligogenic model of transmission. In this model, the probability of developing pubertal failure, and also the severity of disease, is due to the association of several rare variants in candidate genes. The frequency of this oligogenic transmission remains unknown. The fact that AAM and age at puberty are polygenic traits with hundreds of loci involved strongly supports the hypothesis that some cases of delayed puberty and even absent puberty could be transmitted as an oligogenic trait or even could be considered as part of a polygenic disorder. That CHH may be reversible in adulthood in a significant proportion of patients is probably related to this polygenic effect. Up to 20% of cases exhibit a spontaneous recovery of reproductive function ([@bib55], [@bib201], [@bib219]), challenging the dogma that the CHH is (i) a life-long condition and (ii) a distinct entity from self-limited delayed puberty. We can hypothesize that there is a spectrum of pathology spanning between absolute GnRH deficiency and delayed puberty, with severe delayed puberty, partial CHH, and reversible CHH potentially lying along this spectrum. Genetic diagnosis in these patients may well help to unpick this clinical complexity. The greater mutational burden seen in patients with more severe disease, with those with KS or CHH carrying homozygous pathogenic mutations or multiple disease-causing mutations (digenicity or oligogenicity), is in support of this concept, although it is likely that some aspects of the genetic profiles of CHH and delayed puberty will be distinct ([@bib220]).

These discoveries are critical in enhancing the understanding of the regulation of the HPG axis at puberty. Despite recent advances, with \>40 genes linked to this disorder identified, the pathophysiological basis of CHH in ∼50% of individuals remains unclear ([Fig. 3](#fig3){ref-type="fig"}) ([@bib194]). There is a greater or lesser degree of phenotypic variability depending on the gene involved, with nearly all mutations in *ANOS1* (OMIM 300836) leading to HH with anosmia (KS), whereas loss-of-function mutations in *FGFR1* (OMIM 136350) have been identified in pedigrees with KS, normosmic HH, and delayed puberty. Environmental factors may partially explain these variations, but it is increasingly clear that gene--gene interactions in CHH are an important phenomenon, and strategies to identify such digenic and even oligogenic inheritance in families are developing ([@bib201]). In such kindreds, the pattern of those affected by disease may not conform to classic Mendelian inheritance dogma and bioinformatic filtering pipelines, and statistical modeling techniques will require modification to identify novel candidates for such gene--gene interactions.

![Established genetic basis of common genetic variants of pubertal timing, conditions of CHH (IHH and KS), precocious puberty, and delayed puberty and their overlap. Activating and inactivating mutations in Kiss1 and Kiss1R cause the opposite phenotypes, that is, precocious puberty and CHH, respectively. IHH, idiopathic HH.](er.2018-00248f3){#fig3}

Development of the GnRH neuronal network {#s32}
----------------------------------------

Different defects of the GnRH system have been described as resulting in pubertal failure ([Fig. 4](#fig4){ref-type="fig"}): (i) defects in GnRH synthesis, which mainly result from an abnormal migration of GnRH neurons from the olfactory placode toward the hypothalamus during the first trimester of fetal life; (ii) low GnRH secretion due to a defect of GnRH secretagogue bioactivity such as kisspeptin or neurokinin B; (iii) poor maturation of the GnRH neuronal network; and (iv) loss of function of GnRH itself, also known as a defect of the bioactivity of GnRH or its receptor ([@bib46]).

![Mutations in single genes at many levels of the HPG axis can cause HH. \[Copyright © 2012 Beate K, Joseph N, Nicolas de R, Wolfram K. Genetics of isolated hypogonadotropic hypogonadism: role of GnRH receptor and other genes. Int J Endocrinol. 2012;2012:147893. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.\]](er.2018-00248f4){#fig4}

The development of the HPG axis is exceptional in that GnRH neurons develop in metazoan embryos outside the CNS ([@bib221]). The embryonic migration of GnRH neurons from nose to hypothalamus is key for the development of the neuroendocrine pathways that allow normal pubertal development ([@bib222]). At the end of their journey, GnRH neurons dissociate from guiding axons to disperse into their final positions of the septohypothalamic region, including the medial septum, the diagonal of Broca, and the preoptic area of the hypothalamus ([@bib223]). GnRH neurons extend their neurites to the median eminence under the control of mostly unknown factors ([@bib224]). FGFR1 signaling has been shown to be important for this process of axon extension, with reduced projections to the median eminence in transgenic mice expressing a dominant-negative FGF receptor in GNRH1 neurons ([@bib225]).

Migratory GnRH neurons receive a plethora of guidance and movement-inducing messages during this journey, which are likely to be distinct depending on the stage of their migration ([Fig. 5](#fig5){ref-type="fig"}) ([@bib222]). Signals may act directly or indirectly through the extension of olfactory axons, as disruption of the nerve tract "scaffolds" themselves can disrupt GnRH migration ([@bib226]). The molecular signals involved include those controlling cell--cell interactions \[membrane receptors (*e.g.*, neuropilin-2), adhesion molecules (*e.g.*, NCAM), extracellular matrix molecules (*e.g.*, heparin sulfotransferases), cytokines (*e.g.*, leukemia inhibitory factor, hepatocyte growth factor), and transcription factors (*e.g.*, Ebf-2), as well as both chemoattractants and chemorepellents (*e.g.*, Reelin) ([@bib227]\]. Gradients of chemokines (*e.g.*, SDF1, also known as CXCL12) may be particularly important for promoting movement of GnRH neurons ([@bib226], [@bib232]). This combination of factors has a high degree of redundancy, which is necessary given the crucial role that this GnRH neural network plays in reproductive function.

![Factors that affect the migration of GnRH neurons through the three compartments. The illustration shows the movement of GnRH neurons from their origin in the nasal placode (NP), through the nasal compartment (NC), and their deflection at the level of the nasal--forebrain junction (NFJ) as they progress toward the basal forebrain (BF). Their migration terminates in the hypothalamus (H) from where they project to the median eminence (ME). Factors that have been shown to affect GnRH neurons at different stages of their journey are shown below. CCK, cholecystokinin; CXCR4, CXC chemokine receptor type 4; Ebf-2, early B-cell factor 2; HGF, hepatocyte growth factor, LIF, leukemia inhibitory factor; Npn-2, neoplastic progression 2; SDF1, stromal cell--derived factor 1. \[Republished with permission of Oxford University Press, from Cariboni A, Maggi R, Parnavelas JG. From nose to fertility: the long migratory journey of gonadotropin-releasing hormone neurons. Trends Neurosci. 2007;30(12):638--644. Permission conveyed through Copyright Clearance Center, Inc.\]](er.2018-00248f5){#fig5}

The whole process of migration involves a few hundred neurons per hemisphere in mice (several thousand in primates or humans) ([@bib222]). The absolute number of GnRH neurons required for pubertal development is not known but there appears to be a degree of redundancy in the system ([@bib233]). Rodent studies suggest that ∼12% of the GnRH neuron population is sufficient for pulsatile gonadotropin secretion and puberty onset, whereas between 12% and 34% is required for cyclical control in adult female mice. Additionally, adult Reeler mice have significantly fewer GnRH neurons in the hypothalamus and display a phenotype of delayed pubertal maturation and low fertility ([@bib228]).

*ANOS1* (OMIM 300836) encodes anosmin-1, an extracellular matrix protein that regulates axonal path finding and cellular adhesion. Anosmin-1 promotes branching of olfactory bulb neurons. Subjects with *ANOS1* loss-of-function mutations have arrest of both GnRH neurons and olfactory bulb neurons at the cribriform plate ([@bib234]). It is not yet clear whether the effects of anosmin-1 are limited to the development of olfactory neurons, or whether it has an additional chemotactic influence on GnRH neurons ([@bib235]). Although no mouse model is available, fish and nematode studies and *in vitro* work have further elucidated the role of *ANOS1* ([@bib236]).

Upstream control of GnRH neuronal function {#s33}
------------------------------------------

The master controller of the GnRH neuronal pulse generator controlling the onset of puberty is still a subject of active research ([@bib237]). GnRH is secreted in a pulsatile fashion into the hypothalamic--pituitary--portal system by nerve terminals located in the median eminence to reach the anterior pituitary where it stimulates the gonadotropins LH and FSH secretion by pituitary gonadotrope cells. GnRH is released in episodic boluses, and the secretion of GnRH pulses is synchronized between GnRH neurons, such that they integrate their firing rates to generate an appropriate burst of GnRH release into the portal system ([@bib238]). This synchrony is a complex process involving spontaneous electrical activity of the neurons, calcium and cAMP signaling, autocrine regulation through the GnRH receptor, and regulation through other cell membrane receptors on these neurons.

The theory that the pulse generator is an intrinsic property of GnRH neurons has been mostly rejected, given evidence derived from models such as retrochiasmatic rat hypothalamic explants, which contain few if any GnRH cell bodies, but continue to exhibit pulsatile GnRH release in culture ([@bib239]). Retrograde tracing studies in mice have shown that GnRH neurons are subject to a complex neuronal network of inputs from many regions of the brain, including hypothalamic nuclei, the brainstem, limbic system, basal ganglia, and motor and sensory circuits ([@bib240]). GnRH release is coordinated through a balance of inhibitory and excitatory neuronal and glial inputs ([@bib241]) ([Fig. 6](#fig6){ref-type="fig"}).

![Genetic regulators in the trans-synaptic and glial control of GnRH neurons during puberty. + Represents an activating signal, whereas − represents a repressing signal. \[Adapted with permission from Ojeda SR, Lomniczi A, Mastronardi C, *et al.* Minireview: the neuroendocrine regulation of puberty: is the time ripe for a systems biology approach? Endocrinology. 2006;147(3):1166--1174.\]](er.2018-00248f6){#fig6}

Among various regulators of GnRH neurons, kisspeptins and neurokinin B are essential inputs. This "KNDy" model of pulse generation has key neurons in the ARC as responsible for coordinating pulse generation through the peptides kisspeptin, neurokinin B, and dynorphin ([@bib187]). Kisspeptin, an excitatory neuropeptide, was identified as a vital permissive factor in puberty onset by the discovery of patients with GnRH deficiency with loss-of-function mutations in *KISS1R* (OMIM 604161), previously known as *GPR54* ([@bib242], [@bib243]). Mice with knockout of *Kiss1r* were simultaneously discovered to be infertile despite anatomically normal GnRH neurons and normal hypothalamic GnRH levels ([@bib243]). Their phenotype can be rescued by exogenous delivery of GnRH. *Kiss1* (OMIM 603286) knockout mice also have a phenotype consistent with normosmic GnRH deficiency.

Kisspeptins are synthesized by hypothalamic neurons that are in close contact with GnRH neurons. Most GnRH neurons express the kisspeptin receptor, and kisspeptin neurons express steroid receptors including estrogen receptor *α*, the progesterone receptor, and the androgen receptor ([@bib244]). These neurons are the main relay for the negative and positive feedback of steroid hormones on the gonadotropic axis ([@bib245]). Axonal ends of kisspeptin neurons project to the GnRH neuron cell body in the *organum vasculosum laminae terminalis*, but also to the median eminence where they are in apposition with the extremities of GnRH neurons ([@bib246]). Kisspeptin neurons are located outside the blood--brain barrier and are therefore directly in contact with peripheral hormones.

Kisspeptin thus signals directly to GnRH neurons to control pulsatile GnRH release. It is upregulated in both primates and mice in the peripubertal period and its administration in prepubertal rodents advances the onset of puberty ([@bib247]). Kisspeptin also appears to be downregulated in functional amenorrhea, suggesting its role as a mediator of the action of environmental factors such as nutritional status and emotional well-being on puberty and reproductive capacity. Additionally, kisspeptin has been shown to be an important neuroendocrine regulator of ovulation ([@bib248]). Kisspeptin signaling is an important element of both positive and negative feedback loops in the HPG axis. Although kisspeptin has been identified as a pivotal upstream regulator of GnRH neurons, whether it is the key factor in triggering the onset of puberty remains unclear ([@bib248], [@bib249]).

An additional excitatory neuropeptide, neurokinin B, has been implicated in the upstream control of GnRH secretion ([@bib250]). Identification of this pathway was also via discovery of loss-of-function mutations in *TAC3* (OMIM 162330), encoding neurokinin B, and its receptor *TACR3* (OMIM 162332) in patients with normosmic HH and pubertal failure ([@bib198], [@bib251]). Kisspeptin neurons located in the ARC, which synthesize neurokinin B and dynorphin A, are known as KNDy neurons. Both *KISS1* and *TAC3* expression in the ARC is downregulated by estrogen, and these neurons are considered as the relay of the negative feedback of steroid hormones on the gonadotropic axis ([@bib252]). KNDy neurons express the neurokinin receptor, NK3R, suggesting that autocrine and paracrine loops control GnRH release ([@bib253]). Dynorphin inhibits the release of GnRH and together these peptides are thought to play a fundamental role in the GnRH pulse generator.

Another RF-amide related peptide (RFRP, OMIM 616984), the mammalian ortholog of the avian peptide gonadotropin-inhibiting hormone (*GnIH*), has emerged as a further inhibitory regulator of the gonadotropic axis by directly controlling GnRH neurons ([@bib254]) and via a subset of kisspeptin neurons ([@bib255]). GnIH plays a crucial role in the inhibitory regulation of the HPG axis in several species. In addition to neuropeptides, several neurotransmitters participate in the control of the GnRH network. In the ARC, GABA and glutamate control GnRH neuronal excitability ([@bib256]). In female rats, glutamine synthase is downregulated and glutamate dehydrogenase becomes more abundant in the hypothalamus at puberty, both leading to increased availability of glutamate ([@bib257]). Glutamate antagonists are potent stimulators of GnRH secretion, and administration to prepubertal primates can stimulate the onset of puberty. The GABA neural network is quite complex because some of these neurons will have a direct effect on GnRH neurons and others will act on interneurons. The inhibitory role of GABAergic neurotransmission in restraining the initiation of puberty has been clearly shown in primates but is more ambiguous in rodents ([@bib258]). GABAergic signaling pathways are likely to be important in the stress-induced suppression of LH.

The synchronous pulsatile secretion of GnRH is also controlled through the activation of neuronal--glial signaling pathways ([@bib259], [@bib260]). Glial inputs appear to be predominantly facilitatory and consist of growth factors and small diffusible molecules, including TGF*β*1, IGF-1, and neuregulins, that directly or indirectly stimulate GnRH secretion ([@bib261]). First, glial cells in the median eminence regulate GnRH secretion by production of growth factors acting via receptors with tyrosine kinase activity. FGF signaling is required for GnRH neurons to reach their final destination in the hypothalamus ([@bib225]), as well as for GnRH neuronal differentiation and survival ([@bib262]). Additionally, GnRH neuron secretory activity is facilitated by IGF-1 and by members of the epidermal growth factor family such as neuregulin 1*β* ([@bib261], [@bib263]). Second, plastic rearrangements of glia--GnRH neuron adhesiveness mediated by soluble molecules such as neuronal cell adhesion molecule and synaptic cell adhesion molecule coordinate the controlled delivery of GnRH to the portal vasculature, a process that is also subject to sex steroid regulation ([@bib264]). These neural and neuroendocrine regulators are ultimately responsible for fine-tuning the pulsatile secretion of GnRH into the hypophysial portal circulation ([@bib265]) to control the next level of this hierarchical regulatory cascade, that is, the gonadotrope cells of the anterior pituitary gland.

Puberty is marked by the change of the balance of GABA--glutamate signaling in the brain ([@bib256]). This is associated with a higher dendritic spine density and a simplification of the dendritic architecture of GnRH neurons. The timing of puberty is also correlated to an increase of the kisspeptin signaling in the hypothalamus that is due to an increase of kisspeptin synthesis as well as an increased responsiveness of GnRH neurons to kisspeptin stimulation. Although mainly described in mice, this paradigm is probably true in monkeys as well and relatively well conserved during evolution ([@bib266]).

The mechanisms responsible for the increased biosynthesis of kisspeptins at the end of the juvenile period in the hypothalamus remain unknown. Data pointing to hypothalamic regulation via a hierarchical network of genes ([Fig. 6](#fig6){ref-type="fig"}) have come mainly from a systems biology approach ([@bib267]) and animal models ([@bib187]) with little data from human subjects. Candidate transcriptional regulators identified by these approaches include *Oct-2* (OMIM 164176), *Ttf-1* (OMIM 600635), and enhanced at puberty 1 (*Eap1*, OMIM 611720). *Oct-2* is a transcriptional regulator of the POU-domain family of homeobox-containing genes. *Oct-2* mRNA is upregulated in the hypothalamus in juvenile rodents; blockage of Oct-2 synthesis delays age at first ovulation, and hypothalamic lesions that induce precocious puberty (*e.g.*, hamartomas) activate Oct-2 expression ([@bib268]). *Ttf-1* is another homeobox gene that enhances GnRH expression ([@bib269]). *Ttf-1* expression is increased in pubertal rhesus monkeys ([@bib270]). *Eap1* mRNA levels also increase in the hypothalamus of primates and rodents during puberty, *Eap1* transactivates the *GnRH* promoter, and Eap1 knockdown with small interfering RNA caused delayed puberty and disrupted estrous cyclicity in a rodent model ([@bib271]). *Eap1* gene expression itself seems to be under dual transcriptional regulation by *Ttf-1* activation and *Yy1* (OMIM 600013) and *Cux1* (OMIM 116896) repression ([@bib276]).

Recent data have highlighted the importance of a transcriptional repressive program that controls the expression of *Kiss1.* The intervention of the polycomb complex proteins EED (OMIM 605984) and Cbx7 (OMIM 608457) in the transcriptional repression of *Kiss1* (OMIM 603286) is thought to be an important mechanism preventing the premature initiation of puberty ([@bib277]). The expression of these genes in the prepubertal period decreases with increasing methylation of their promoters. The binding of EED on the *Kiss1* promoter decreases at puberty. The inhibition of the repression of *Kiss1* is also correlated to a decrease in the expression of transcription factors with zinc finger motifs. Importantly, the loss of these polycomb complex proteins from the promoter is accompanied by a reorganization of the chromatin status and changes in histone methylation ([@bib278]).

Additionally, the role of noncoding RNAs as epigenetic modulators of pubertal timing has been illustrated in a mouse model of GnRH-specific impaired miRNA synthesis. A key pair of miRNAs \[miR-200 (OMIM 612090-2) and mIR-155 (OMIM 609337)\] has been proposed to control the expression of Gnrh (OMIM 152760), Zeb-1 (OMIM 189909), and Cebpb (OMIM 189965), with the latter two being both potent transcriptional repressors of Gnrh. At puberty there is a switch in activity with a decrease in the transcriptional activation of the GnRH gene and an increase in Zeb-1 and Cebpb, leading to the rise of *GNRH1* synthesis, which occurs during the juvenile period in GnRH neurons ([@bib169]). The increase of kisspeptin expression in the hypothalamus therefore results from a complex network of transcription factors acting as repressors and activators of *Kiss1* and *GNRH1* transcription, with these in turn being under the influence of a number of different epigenetic mechanisms, including DNA methylation, histone modification, and noncoding RNAs ([@bib169], [@bib278]). The plasticity of GnRH neurons to kisspeptin stimulation is more obscure. The kisspeptin receptor is a G-protein--coupled receptor coupled to G~q/11~ protein. The regulation of G-protein--coupled receptor activity is multifactorial ([@bib281]). G-protein--coupled receptors can undergo acute but also chronic desensitization through multiple intracellular signaling pathways and regulatory proteins. This regulation is thought to be associated with the maturation status of GnRH neurons.

The concept that puberty results from the disappearance of gonadotropic axis repression is also supported by the description of loss of function mutations of *MKRN3* (OMIM 603856) in familial CPP ([@bib162], [@bib282], [@bib283]). This gene encodes makorin ring finger protein 3, a zinc finger protein containing a C3HC4 motif termed a RING domain associated with E3 ubiquitin ligase activity. MKRN3 is likely to have an inhibitory effect on the GnRH network because its expression in the ARC decreases in mice between birth and weaning and circulating levels in humans decline at puberty onset ([@bib284], [@bib285]). Where *MKRN3* might be placed in the hierarchical network of genes controlling kisspeptin has yet to be determined.

Puberty must thus be considered as the output of a neurodevelopmental program, which shares several features with the postnatal development of other neuronal functions. The specificity of this program resides in its timing, which is determined by genetic factors dependent on the hormonal status and modulated by environmental factors. It is not surprising that delayed puberty and even absent pubertal development are not infrequent pathologies observed in humans.

Downstream pathways of GnRH action {#s34}
----------------------------------

Loss-of-function mutations within the GnRH receptor are the most frequent cause of autosomal recessive CHH, accounting for 16% to 40% of patients. Mutations have been found within the extracellular, transmembrane, and intracellular domains of the receptor leading to impaired GnRH action ([@bib286]). LH and FSH are glycoprotein hormones encoded by a common *α*-subunit gene and a specific *β*-subunit gene. Mutations of the *β*-subunits of LH or FSH are rare causes of HH ([@bib287], [@bib288]). Females with inactivating mutations of *LHβ* (OMIM 152780) present with onset of normal puberty and normal or late menarche followed by infertility due to lack of ovulation. Males with inactivating mutations of the *LHβ*-subunit have absent pubertal development with Leydig cell hypoplasia leading to testosterone deficiency and azoospermia. Individuals with inactivating *FSHβ* (OMIM 136530) mutations present with incomplete pubertal development and primary amenorrhea in females and azoospermia in males ([@bib289]).

Genetics of Self-Limited Delayed Puberty {#s35}
========================================

Self-limited delayed puberty segregates within families with complex patterns of inheritance, including autosomal dominant, autosomal recessive, bilineal, and X-linked, although sporadic cases are also observed. Most families display an autosomal dominant pattern of inheritance (with or without complete penetrance) ([@bib290]). Fifty percent to 75% of subjects with self-limited delayed puberty have a family history of delayed pubertal onset ([@bib291]). Self-limited delayed puberty is not sex specific, as near equal sex ratios among family members are seen ([@bib292]). Although a predominance of males presenting with the condition has been noted, this may be a consequence of referral bias.

The neuroendocrine pathophysiology and its genetic regulation remain unclear in most patients with delayed puberty ([@bib293], [@bib294]). Analysis of self-limited delayed puberty families is complicated by the fact that this phenotype represents the tail of a normally distributed trait within the population, so it is expected that variants that govern the inheritance of this condition may also be present in the general population at a low level. Thus, the absence of these variants in population databases cannot be used as an exclusion criterion during filtering of sequencing data. Instead, a comparison of prevalence of such variants must be made to identify those that are enriched in patients compared with the general population.

Overlap with CHH {#s36}
----------------

In view of the possible overlap between the pathophysiology of delayed puberty and conditions of GnRH deficiency, a few groups have specifically examined the contribution of mutations in CHH genes to the phenotype of self-limited delayed puberty. Studies in cohorts of kindreds with CHH have previously described mutations in *HS6ST1*, *FGFR1*, and more recently in klotho beta (*KLB*) in a small number of CHH individuals and their relatives with delayed puberty ([@bib56], [@bib204], [@bib295]). Most recently, a comparative study of the frequency of mutations in 24 GnRH deficiency genes between probands with CHH and those with self-limited delayed puberty found a significantly higher proportion of mutations in the CHH group (51% of CHH probands vs 7% of delayed puberty probands, *P* = 7.6 × 10^−11^), with a higher proportion of oligogenicity in the CHH group, suggesting mostly distinct genetic profiles in these two conditions ([@bib220]). Mutations in KS genes such as *ANOS1* and *NSMF* have not to date been identified in pedigrees with delayed puberty.

In studies specially examining delayed puberty cohorts, variants in several CHH genes, including *GNRHR*, *TAC3*, *TACR3*, *IL17RD*, and *SEMA3A*, have been identified by whole-exome sequencing ([@bib296]). However, these variants have not been tested *in vitro* or *in vivo* for pathogenicity, or investigated for segregation with trait within pedigrees, and thus they may represent an overestimation.

Using whole-exome and targeted resequencing methods, a deleterious mutation in the CHH gene *HS6ST1* was recently found as the likely causal factor for self-limited delayed puberty in one extended pedigree from the same large cohort of patients with familial delayed puberty ([@bib297]). The mutation was carried by six family members from three generations, all with typical features of self-limited delayed puberty. The proband had spontaneous onset of puberty at 14.3 years. Parallel studies in a murine model corroborated heterozygous *Hs6st1* deficiency as a cause of delayed pubertal timing without compromised fertility. Thus, *Hs6st1*^+/−^ mice were born at normal Mendelian ratios without obvious defects in GnRH neuron or testes development, but females showed delayed vaginal opening, a marker of pubertal onset in female rodents. GnRH deficiency was excluded both in male and female *Hs6st1*^*+/−*^ mice by reproductive competence and by normal spermatogenesis in males.

No abnormalities in olfactory bulb morphology, GnRH neuron number in the medial preoptic area, or in GnRH neuron innervation of the median eminence were detected in *Hs6st1*^*+/−*^ mice. Instead, *Hs6st1* expression in the ARC and paraventricular nucleus, where kisspeptin neurons and tanycytes modulate GnRH secretion and function ([@bib298], [@bib299]), raises the possibility that HS6ST1 haploinsufficiency affects the regulation of GnRH neuron activity or other relevant downstream pathways. These findings suggest that perturbations in a single allele of a gene regulating the HPG axis are sufficient to cause self-limited delayed puberty. In contrast, available evidence supports that more deleterious alterations in the same gene, or in combination with additional genes, are required to cause more severe CHH phenotypes ([@bib201]).

In support of this, using a similar approach with whole-exome and targeted resequencing methods, two pathogenic mutations in immunoglobulin superfamily member 10 (*IGSF10*) have been implicated as the causal factor for late puberty in six unrelated families from a large Finnish cohort with familial self-limited delayed puberty ([@bib300]). A further two rare variants of unknown significance were identified in four additional families from the cohort. Mutations in *IGSF10* appear to cause a dysregulation of GnRH neuronal migration during embryonic development ([Fig. 7](#fig7){ref-type="fig"}), which presents in adolescence as delayed puberty without previous constitutional delay in growth. An intact GnRH neurosecretory network is necessary for the correct temporal pacing of puberty. Pathogenic *IGSF10* mutations leading to disrupted IGSF10 signaling potentially result in reduced numbers, or mis-timed arrival, of GnRH neurons at the hypothalamus, producing a functional defect in the GnRH neuroendocrine network. With this impaired GnRH system there would follow an increased "threshold" for the onset of puberty, with an ensuing delay in pubertal timing. *IGSF10* loss-of-function mutations were also discovered in patients with a hypothalamic amenorrhea-like phenotype. Although loss-of-function mutations in *IGSF10* were enriched in patients with CHH, these mutations did not alone appear sufficient to cause the phenotype of full GnRH deficiency, in view of lack of complete segregation with trait. These findings represent a fetal origin of self-limited delayed puberty, and they suggest a potential shared pathophysiology between delayed puberty and other forms of functional hypogonadism such as hypothalamic amenorrhea.

> *"The mystery of what induces the dormancy of the HPG axis after mini-puberty and what triggers the release of this "puberty brake" remains unanswered."*

![Schematic of the mechanism by which *IGSF10* mutations lead to delayed puberty. Reduced levels of *IGSF10* expression during embryogenesis in the corridor of nasal mesenchyme from the vomeronasal organ (VNO) to the olfactory bulbs result in delayed migration of GnRH neurons to the hypothalamus. This presents for the first time in adolescence as a phenotype of delayed puberty due to abnormalities of the GnRH neuronal network.](er.2018-00248f7){#fig7}

As loss-of-function mutations within the GnRH receptor are one of the most frequent causes of CHH, the *GNRHR* gene has been repeatedly sequenced in patients with self-limited delayed puberty ([@bib286]). However, only a small number of pathogenic mutations in this gene have been identified in this cohort of patients. A homozygous partial loss-of-function mutation in *GNRHR* was found in two brothers, one with self-limited delayed puberty and one with CHH ([@bib301]), and a further heterozygous mutation was found in one male with self-limited delayed puberty ([@bib302]). Overall, the current picture indicates that the genetic background of CHH and delayed puberty may be largely different, or shared by as yet undiscovered genes ([@bib302]).

Overlap with common genetic variants of pubertal timing {#s37}
-------------------------------------------------------

Rare heterozygous variants in *FTO* have been identified in pedigrees with self-limited delayed puberty associated with extreme low BMI and maturational delay in growth in early childhood ([@bib303]). Notably, mice that were heterozygous for *FTO* gene knockout displayed significantly delayed timing of puberty without marked reduction in body mass. *FTO* was the first obesity-susceptibility gene identified through GWASs and continues to be the locus with the largest effect on BMI and obesity risk ([@bib304]). *FTO* appears to exert this effect via influence on food intake regulation rather than physical exertion ([@bib305]), although its actions may be complex ([@bib306]). The finding of the importance of Iroquois homeobox 3 (*IRX3*), a second gene found at the same GWAS locus, in influencing BMI threw into doubt the primary role of *FTO* ([@bib307]). However, the body of evidence behind *FTO*, in particular the results from *FTO*-knockout mice ([@bib308]) and *in vitro* studies showing that FTO expression is regulated by essential amino acids and that it couples amino acid levels to mTORC1 signaling ([@bib309]), have reinforced *FTO* as a major player in the regulation of body mass, although it may also act in concert with other genes in the nearby region to exert effects on body weight. A novel concept in the analysis of GWAS data is that a number of genes in any one identified region may play an important role in a particular phenotype. There is evidence that mTOR plays a central role in the coupling of energy balance and HPG axis activation via modulation of hypothalamic expression of Kiss1 ([@bib310]). Blockade of mTOR caused delayed vaginal opening in rodents with blunting of the positive effects of leptin on puberty onset in food-restricted females. It remains to be determined whether the effect of *FTO* on pubertal timing in self-limited delayed puberty is mediated via effects on body mass, via mTOR signaling, or both.

Roles for other genes connected with regulation of body mass have not been clearly demonstrated in delayed puberty. *α*-MSH signaling via MC3/4 receptors, acting to increase Kiss1 expression and mediate the permissive effects of leptin on puberty, has also been implicated recently as an important element in the metabolic control of puberty ([@bib311]). As mentioned above, ghrelin and other gut-derived peptides may also form part of the mechanism by which energy homeostasis regulates reproductive development ([@bib190], [@bib312]). A small cohort of 31 patients was analyzed for mutations in the ghrelin receptor, or GH secretagogue receptor (*GHSR*), and 5 patients were found to have point mutations in this gene ([@bib313]).

Gene defects relevant to self-limited delayed puberty but not to CHH {#s38}
--------------------------------------------------------------------

Loss-of-function mutations in a member of the immunoglobulin superfamily, immunoglobulin superfamily member 1 (*IGSF1*), have been identified in patients with X-linked central hypothyroidism ([@bib314]). Male patients with *IGSF1* mutations have a late increase in testosterone levels with a delayed pubertal growth spurt. However, pathogenic mutations in *IGSF1* have not been conclusively found in patients with isolated delayed puberty ([@bib315]).

A very recent discovery is of the first human *EAP1* mutations that appear to be causal for self-limited delayed puberty in two families ([@bib316]). The two affected probands had classic clinical and biochemical features of self-limited delayed puberty presenting at more than 15.5 years but spontaneous pubertal development by the age of 18 years without testosterone therapy excluding CHH. Two highly conserved variants in *EAP1* were identified via whole-exome sequencing---one in-frame deletion and one rare missense variant. Using a luciferase reporter assay, *EAP1* mutants showed a reduced ability to trans-activate the GnRH promoter compared to wild-type *EAP1*, owing to reduced protein levels caused by the in-frame deletion and subcellular mislocation caused by the missense mutation. This study also demonstrated by chromatin immunoprecipitation that EAP1 binding to the GnRH1 promoter increases in monkey hypothalamus at the onset of puberty.

Perspectives {#s39}
============

Puberty is the period of sexual maturation when the transition to adult reproductive capacity, body composition, and adult height occurs. Its biological control is complex and involves multiple endocrine systems interacting in an ordered and progressive pattern. The origins of these biological processes begin early in fetal life, and fetal and neonatal developments are important to allow puberty to occur in an ordered and timely fashion in adolescence. The mystery of what induces the dormancy of the HPG axis after mini-puberty and what triggers the release of this "puberty brake" remains unanswered. There are multiple influences on the timing of puberty in the general population, and a wide variety of genetic, epigenetic, and environmental factors affecting different aspects of the HPG axis at different time periods in fetal and postnatal life may result in delayed and disordered puberty.

With respect to clinical practice, delayed puberty is a frequent problem presenting to the pediatric endocrinologist. Whereas the most common underlying condition in delayed onset of puberty is self-limited (or constitutional) delayed puberty, other pathological causes may underlie these conditions and must be excluded. In particular, distinguishing between self-limited delayed puberty and permanent HH in adolescence remains difficult, but the latter can be diagnosed in infancy when the suspicion arises. Management of adolescents with pubertal disorders is dependent on the underlying cause. Expectant observation is appropriate in benign variants of puberty and in those with milder forms of delayed puberty who are not predicted to have negative outcomes from their condition. Treatment of more significant precocious or delayed puberty involves medication to block or induce activity of the HPG axis, although more complex and involved management is required in patients with permanent hypogonadism. Achievement of fertility in patients with central hypogonadism requires therapy with gonadotropins.

Therefore, although genetic testing may inform diagnosis of associated syndromic features, natural history of the condition, and inheritance in family members, it may also represent a future diagnostic tool for the differentiation of the conditions of self-limited delayed puberty and GnRH deficiency. Rapid and efficient diagnosis of patients in the clinic would represent a huge leap forward in patient care and a likely significant economic advantage.

Conclusions {#s40}
===========

This review serves to highlight the fascinating heterogeneity of genetic defects resulting in delayed and disordered puberty, with a special emphasis on a condition called self-limited delayed puberty. Investigation of the genetic control of delayed puberty is complicated by the facts that this trait is not rare and that the phenotype is likely to represent a final common pathway, with a variety of different pathogenic mechanisms affecting the release of the puberty "brake." Although our understanding of the highly complex mechanisms underlying this biological network remains imperfect, results to date have demonstrated the importance of defects in GnRH neuronal development and function, including GnRH receptor and LH/FSH abnormalities, transcriptional regulation of the HPG axis, and metabolic and energy homeostatic derangements, in the pathogenesis of delayed puberty. Most recently the complex network of transcription factors acting as repressors and activators of the kisspeptin and GnRH system, as well as their higher control by a number of different epigenetic mechanisms, including DNA methylation, histone modification, and noncoding RNAs, has sparked great interest. Thus, genetic regulators of pubertal timing can exert their influence from early fetal life via development of the GnRH network, through prenatal and postnatal development and onwards to middle childhood, and potentially mediate the effects of environmental influences on pubertal timing.

In summary, the considerable progress in understanding the genetic control of puberty during the last 10 years has been a success story of basic research in neuroendocrinology but has also been translated into clinical practice to allow a better understanding of the etiopathogenic mechanisms of disordered pubertal development and, in some cases, to enable diagnostic genetic testing and counseling.
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AAM

:   age at menarche

AMH

:   anti-Müllerian hormone

ANOS1

:   anosmin 1

ARC

:   arcuate nucleus

BMI

:   body mass index

CHARGE

:   coloboma, heart malformations, atresia of the choanae, retardation of growth and development, genital anomalies, and ear anomalies (auditory and vestibular)

CHD7

:   chromodomain helicase DNA binding protein 7

CHH

:   congenital HH

CNS

:   central nervous system

CPP

:   central precocious puberty

DLK1

:   delta-like noncanonical Notch ligand 1

Eap1

:   enhanced at puberty 1

EDC

:   endocrine-disrupting chemical

FGF

:   fibroblast growth factor

FGFR1

:   FGF receptor 1

FTO

:   fat mass and obesity-associated protein

GABA

:   *γ*-aminobutyric acid

GWAS

:   genome-wide association study

GNRHR

:   GnRH receptor

HH

:   hypogonadotropic hypogonadism

HPG

:   hypothalamic--pituitary--gonadal

HS6ST1

:   heparin sulfate 6-*O*-sulfotransferase 1

IGSF1

:   immunoglobulin superfamily member 1

IGSF10

:   immunoglobulin superfamily member 10

IL17RD

:   IL-17 receptor D

KISS1

:   kisspeptin 1

KISS1R

:   KISS1 receptor

KS

:   Kallman syndrome

LEPR

:   leptin receptor

MKRN3

:   makorin ring finger protein 3

NHANES III

:   Third National Health and Nutrition Examination Survey

NPY

:   neuropeptide Y

NR0B1

:   nuclear receptor subfamily 0 group B member 1

NR5A1

:   nuclear receptor subfamily 5 group A member 1

Oct-2

:   organic cation transporter 2

PWS

:   Prader--Willi syndrome

RA

:   retinoic acid

SEMA3A

:   semaphorin 3A

TAC3

:   tachykinin 3

TACR3

:   tachykinin receptor 3

Ttf-1

:   thyroid transcription factor-1
